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ABSTRACT 
Breast cancer is the most common malignancy and a major cause of cancer-
related death among Canadian women.  Although treatment of primary breast tumours is 
highly successful through surgery, metastatic breast cancer is difficult to treat.  Cancer 
progression and metastasis require the accumulation of numerous genetic and epigenetic 
alterations.  Normal cells that acquire such alterations can transform into cancer cells, 
resulting in primary tumour formation.  Primary tumours are a heterogeneous population, 
containing cells of various metastatic potentials.  Cells that acquire a high potential for 
metastasis can spread to secondary locations.  Our model system consists of two 
subpopulations, with different metastatic potential, derived from the same rat mammary 
adenocarcinoma.  Using this model, a differentially expressed novel gene, termed MS-1, 
was discovered.  Due to significant expression of this gene in the poorly metastatic 
subpopulation and lack of expression in the highly metastatic subpopulation, MS-1 may 
have involvement in metastasis suppression.  Several breast cancer metastasis suppressor 
genes have been identified on the basis that they are down-regulated during the 
progression of metastasis.  Epigenetic mechanisms, such as DNA methylation, account 
for loss of expression in several of these genes.  Hypermethylation of CpG islands within 
gene promoters results in deacetylation of histone proteins and produces a compact 
chromatin structure that is unfavourable for transcription.  A CpG island spans the 5’ 
untranslated region, exon 1 and part of intron 1 of the MS-1 gene.  Our data reveal 
 ii
aberrant methylation patterns of this CpG island between the cell lines of different 
metastatic potential in our model.  Also, MS-1 expression was partially induced by both 
DNA methylation and histone deacetylation inhibitors.  Following a screen of several 
cancer cell lines of varying metastatic potential, it appears that the presence of DNA 
methylation in the CpG island of MS-1 correlates with the lack of MS-1 expression.  
Therefore, these results suggest that MS-1 may be silenced in cells of high metastatic 
potential through epigenetic mechanisms. 
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1.0 LITERATURE REVIEW 
 
1.1 Breast Cancer and Metastasis 
Breast cancer is the most common malignancy and a major cause of cancer-
related death among Canadian women.  One in nine women is expected to develop breast 
cancer during her lifetime and one in 27 will die of it [1].  Most women succumb to 
breast cancer if tumours metastasize but cure rates exceed 90% if breast carcinomas 
remain confined to breast tissue [2].  However, 5-year survival rates fall below 20% if 
secondary metastases form [3].  Statistics show that early detection is essential for 
optimal success in the treatment of breast cancer.  However, a better understanding of the 
metastatic process in human breast cancer should translate into substantial improvements 
in therapeutic outcome for breast cancer patients [2].   
Further understanding could lead to the identification of markers on cells with a 
high probability of causing macroscopic metastases.  Genetic markers could be used for 
diagnosis of tumour type, grade and maybe disease stage, including prediction of 
metastases location.  Also, a better understanding of metastasis could result in identifying 
gene targets for gene therapy, which may be used as an alternative to chemotherapy [4].  
The identification of genes involved in metastasis could be exploited to alter the 
metastatic cascade.  For example, a mimetic could be developed either to prevent the 
establishment of new metastases or to block the growth of metastases and possibly induce 
regression of the metastases [3]. 
The characteristics of transformed cells include being anchorage-independent, 
contact-uninhibited, immortal and having a several-fold decrease of genomic stability 
compared to normal cells.  Genomic instability appears to be the driving force for the 
accumulation of genetic defects required for cells to become fully tumourigenic [2].  
Tumour progression is the evolution of already tumourigenic cells towards increasing 
malignancy.  Malignancy is characterized by pathologists on the bases of morphologic 
attributes, including less differentiated cytology, vascularity, necrosis, mitotic index, and 
aneuploidy.  Hallmarks of malignancy include invasion of cells through the basement 
membrane and/or metastasis [3]. 
Metastasis is the progressive growth of cells at a site that is discontinuous from 
the primary tumour [3].  Malignant cells invade adjacent tissues and penetrate the 
lymphatic and/or circulatory systems.  Cells can travel independently or as emboli that 
are composed of tumour cells only (homotypic) or of tumour cells and normal cells 
(heterotypic).  Cells or emboli arrest at a secondary site either due to a physical limitation 
or to binding specific molecules in particular organs or tissues.  Tumour cells then 
proliferate in the vasculature or extravasate into surrounding tissue [2].  Cells are able to 
spread through the blood vasculature, lymphatics or within body cavities.  Primary 
tumours contain a heterogeneous population of cells with various metastatic potentials 
[3].  Metastatic potential increases with the acquired the ability to complete each step of 
the metastatic cascade.  Low metastatic potential may be due to inherent deficiencies in 
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the tumour cells themselves caused by genetic alterations or to defective responses to the 
host environment as a result of epigenetic regulation [3]. 
 
1.2 Epigenetics 
 
1.2.1 Epigenetic Code 
Epigenetics is the inheritance of information based on gene expression levels, 
whereas genetics is the transmission of information based on gene sequences [5].  
Epigenetic codes are potentially heritable but can be modified [6].  An epigenetic trait is 
inherited during DNA replication and cell division but is independent of the DNA 
nucleotide sequence itself [7] [8] [9].  Variations in DNA methylation and histone 
modifications constitute a distinct epigenetic code that regulates gene expression.  For 
example, methylated DNA, deacetylated histones, some methylated histone forms and 
condensed chromatin are associated with inaccessible DNA and repressed or silenced 
gene expression whereas unmethylated DNA, some acetylated histone forms and open 
chromatin are associated with active or potential gene expression [6].   
 
1.2.2 Chromatin Structure 
Chromatin is the complex of DNA and proteins in which the genetic material is 
packaged inside the nucleus.  It is organized into condensed heterochromatin and open 
euchromatin.  The nucleosome core particle includes ~145 bp of DNA wrapped around a 
histone octamer core [10] [11].  Histones are the basic protein components of chromatin.  
The nucleosome core particle consists of two copies each of histones H2A, H2B, H3 and 
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H4 [7] [11].  The basic unit of DNA structure is the nucleosome.  Nucleosomes are 
connected by ~10-80 bp of DNA, and are compacted by the linker histone H1 into 
chromatin fibres of ~30 nm in diameter [6].  The complex of the histone octamer, linker 
histone, and 166 bp of nucleosomal DNA is termed the chromatosome [11].  The DNA 
wound around the histone octamer is accessible to regulatory proteins.  The histone tails 
are also accessible, and enzymes can chemically modify them to promote nucleosome 
movement and unwinding [7]. 
There is considerable evidence to suggest that histones are not merely packaging 
factors, but function to regulate gene expression.  Histones facilitate gene activation by 
promoting specific structural interactions between distal sequences and facilitate 
repression by blocking the binding sites for transcription activators.  The rate-limiting 
biochemical response that leads to activation of gene expression involves alterations in 
chromatin structure.  The most compact form is inaccessible and provides a poor template 
for biochemical reactions.  There are several ways the chromatin structure can be altered: 
the histones of the nucleosome can be covalently modified or histone variants can replace 
the core histones [7]. 
 
1.2.3 CpG Islands 
DNA methylation occurs at carbon 5 of cytosine residues 5’ to guanine residues, 
or CpG dinucleotides.  The CpG dinucleotide has been progressively depleted from the 
eukaryotic genome during evolution due to spontaneous deamination of the unstable base 
5-methylcytosine to uracil [12].  Methylated cytosine accounts for ~1% of the total DNA 
bases; however, ~70% of all CpG dinucleotides are methylated [13].  Regions in the 
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genome that contain a high frequency of CpG dinucleotides are referred to as CpG 
islands if they meet the following criteria: size ranging from 0.2 to 5 kb, occurring 
approximately every 100 kb, GC-rich (60-70%) and having a CpG/GC ratio greater than 
0.6 [12].  The human genome contains ~29,000 CpG islands [13].  They generally span 
the 5’ end of some genes, including the promoter, untranslated region and exon 1 [14].  
Most CpG islands remain unmethylated and are associated with highly active genes, such 
as housekeeping genes [13] [15]. 
The transcription of genes is favourable when the appropriate transcription factors 
are available, the histones are acetylated and unmethylated, and the cytosines in the CpG 
island, if present, remain unmethylated [14].  CpG islands are generally protected from 
methylation.  Fully methylated CpG islands are found mostly in promoters of 
retroviruses, transposons, silenced alleles, such as imprinted autosomal genes and genes 
on the inactivated X-chromosome of females [13].  Normal protection of CpG islands 
from methylation is mediated by certain transcription factors.  For example, binding sites 
for the transcription factor Sp1 appear to be critical for protection from methylation [8]. 
 
1.2.4 DNA Methylation 
Genome stability and normal gene expression are maintained by a fixed and 
predetermined pattern of DNA methylation [14].  DNA methylation protects the genome 
from invading foreign DNA elements [6].  DNA methylation is mediated by two classes 
of DNA methyltransferases (DNMTs).  The methylated state of the parent DNA strand is 
maintained in the daughter strands by DNMT1, a maintenance methyltransferase.  
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DNMT1 recognizes the hemimethylated site and methylates the unmethylated cytosine, 
restoring the symmetrically methylated CpG dinucleotide pair [16].   
DNMT3a and DNMT3b are responsible for de novo methylation.  DNMT3a and 
DNMT3b do not have a preference for hemimethylated CpG sites and can methylate 
unmodified CpG sites as well [6].  DNMT3a and DNMT3b are structurally similar to 
DNMT1 but with a regulatory region attached to the catalytic domain.  The regulatory 
region binds a variety of transcriptional repressors [17].  De novo methylation usually 
occurs outside of a promoter CpG island and progressively spreads to the center of the 
island.  There are sequences in the promoter region that serve as a docking site for 
repression complexes including histone deacetylases (HDACs), methyl-CpG-binding 
proteins (MBDs), DNMTs and other proteins [18]. 
DNA methylation involves the addition of a methyl group to the DNA.  A 
cysteine SH group from the active site of the DNMT initiates nucleophilic attack at the 
C6 position of the target cytosine by transient protonation of the cytosine ring at the 
endocyclic nitrogen, N3, creating cytosine-4,5-enamine.  This structure attacks the 
sulphonium linked methyl group of S-adenosylmethionine (SAM).  Following methyl 
transfer, a proton is abstracted from C5, allowing reformation of the 5,6 double bond [9].  
5-aza-2’-deoxycytidine (DAC) is a cytosine analogue that sequesters DNMT after its 
incorporation into genomic DNA and therefore, functions as a DNMT inhibitor [18]. 
DNMTs methylate a specific target cytosine within a DNA molecule.  To achieve 
this specificity the enzyme needs to bring the target cytosine to its catalytic pocket.  The 
target cytosine is rotated on its sugar-phosphate backbone so that the target base is 
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flipped out into a typically concave active site pocket.  This base-flipping phenomenon is 
observed in several DNA methyltransferases [9]. 
Other mechanisms for DNMT specificity exist.  Eukaryotic DNMTs exhibit no 
sequence specificity other than the CpG dinucleotide.  Other factors are likely required to 
mediate the regional genomic specificity they exhibit.  Targeting of DNMTs to particular 
genomic regions may occur through protein-protein interactions.  For example, DNMT1 
is able to bind Rb, the retinoblastoma tumour suppressor protein, which is targeted to a 
specific set of genes through interaction with the sequence-specific DNA-binding factor 
E2F [17].  Methyl-CpG-binding protein, MeCP2, forms complexes with hemimethylated 
as well as fully methylated DNA.  DNMT1 associates with MeCP2 in order to perform 
maintenance methylation [9].  DNMT3a binds RP58, a DNA-binding transcriptional 
repressor, leading to methylation independent repression of the gene at an RP58-
responsive promoter [17].  DNMT3a also associates with HDAC1, leading to histone 
deacetylase-mediated gene silencing [9].  DNMT3a co-localizes with HP1, a 
heterochromatin protein, which binds to methylated histones.  This association could be 
important in directing DNA methylation to chromatin that contains methylated histones, 
leading to long-term silencing [17]. 
Since DNA can be methylated, it is not surprising that it can also be 
demethylated.  Demethylation occurs during DNA replication.  Mechanisms include the 
loss of fidelity in DNMT1 maintenance methylation, exclusion of DNMT1 from 
replication complexes and limiting DNMT1 levels.  The result is that DNA methylation 
patterns are not accurately copied to daughter strand DNA, generating hemimethylated 
CpG sites that can become fully demethylated after rounds of DNA synthesis.  The lack 
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of methylation in CpG islands appears to be passive, either through protection from 
methylation machinery or by the displacement of such machinery.  For example, 
transcription factor Sp1 can bind to a methylated site and sterically exclude 
methyltransferases [6].  It has been shown that SAM actively inhibits demethylase 
activity and can inhibit expression of urokinase plasminogen activator (uPA), a 
metastasis-promoting gene, through induction of methylation-dependent silencing [19].  
The balance between methylation and demethylation is proposed as a mechanism for 
switching the transcription of genes on or off [9]. 
 
1.2.5 Histone Modification 
Tails of histone amino acids protrude from the nucleosome and are sites of post-
translational modification such as acetylation, methylation, phosphorylation, sumoylation 
and ubiquitination [20].  Possible histone modifications represent a complex set of 
epigenetic information with combinatorial potential known as the histone code.  Histone 
interactions with DNA and other proteins are affected by these modifications.  Chemical 
modifications, whether on the histone tails extending from the nucleosome surface or 
within the body of the octamer, serve as signals for the binding of specific proteins [6]. 
The N-terminal tails on core histones are substrates for reversible lysine 
acetylation [21].  Histone acetyltransferases (HATs) and histone deacetylases (HDACs) 
govern the acetylation state of histones.  HDACs remove the acetyl group from histones 
using a charge-relay mechanism consisting of two adjacent histidine residues, two 
aspartate residues and one tyrosine residue, and crucial for this charge-relay system is a 
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Zn2+ ion, which binds deep in the pocket of the enzyme.  Inhibitors such as Trichostatin 
A (TSA), function by displacing the zinc atom [10].   
There are 19 deacetylase enzymes in humans, divided into three classes based on 
differences in structure and function.  The functions of these enzymes include: 
controlling gene expression through targeted and non-targeted chromatin deacetylation, 
promotion of transcriptional repression, and deacetylation of other non-histone proteins 
including transcription factors [21].  Transcriptional activators are often associated with 
HATs, and repressors often interact with HDACs [22].   
The most studied group of HDACs are those of mammalian class I including 
HDAC1, HDAC2, HDAC3 and HDAC8.  HDAC1/2/3-containing complexes serve as 
corepressors for many chromatin and transcriptional regulators.  For example, these 
HDACs collaborate with ATP-dependent chromatin remodelers.  The HDAC1/2 complex 
associates with DNMTs, which are also recruited by transcriptional regulators to repress 
transcription, and histone methyltransferases (HMTs).  HDAC1 interacts with 
topoisomerase II, an enzyme that is essential for chromosome condensation and may be 
involved in gene silencing [21]. 
There are three main mechanisms of histone deacetylase regulation: subcellular 
compartmentalization, post-translational modification and formation of multisubunit 
deacetylase complexes [21].  Association of certain proteins lead to cytoplasmic 
localization of deacetylases by enhancing nuclear export whereas binding of other 
chaperones stimulates nuclear localization.  Increased phosphorylation of HDAC1/2 
disrupts their complexes but specific phosphorylation stabilizes their complexes and 
stimulates deacetylase activity.  Sumoylation of HDAC1 is required for inducing cell-
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cycle arrest and apoptotic responses.  HDACs and their components are also targeted for 
proteolytic processing by ubiquitin-dependent degradation.  Interaction of HDACs with 
certain transcriptional factors dictates targeting specificity to distinct genes or chromatin 
domains [21].  For example, DNA-binding factors recruit the Sin3-HDAC complex and 
result in histone deacetylation, leading to gene silencing [22].   
The Sin3 complex is comprised of at least seven subunits, including HDAC1/2 
and Sin3.  There is an extensive list of mammalian proteins that repress transcription 
through use of the Sin3 complex [22].  Nuclear hormone receptor binds to specific 
promoters in the absence of hormone to repress transcription.  Hormone binding produces 
a conformational change in the complex, converting it to a transcriptional activator with 
help from other recruited proteins.  Unliganded retinoic acid receptor and thyroid 
hormone receptor interact with corepressor proteins SMRT (silencing mediator of 
retinoid and thyroid hormone receptor) and NCoR (nuclear hormone receptor 
corepressor).  SMRT and NCoR lead to transcriptional repression by recruiting the Sin3-
HDAC complex.  Also, the methyl-CpG-binding protein MeCP2 is able to recruit the 
Sin3-HDAC complex to methylated DNA. 
The mammalian NuRD (nucleosome remodelling histone deacetylase) complex 
also has seven subunits including: HDAC1/2, MTA2 and MBD3.  MTA2 is related to 
MTA1 (metastasis-associated protein 1), which is highly expressed in metastatic cells.  
MBD3 (methyl-CpG-binding-domain protein 3) involvement suggests that nucleosome 
remodelling and histone deacetylation abilities of the NuRD complex are targeted to 
methylated regions of the genome [22]. 
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There are several possible mechanisms for repression by histone deacetylation.  
Histone deacetylation may specifically prevent the assembly of the transcription initiation 
complex [22].  Localized histone deacetylation may stabilize nucleosomal structure and 
internucleosomal histone-histone interactions to inhibit the DNA accessibility of 
transcriptional activators and transcriptional machinery [21].  Normally, there is a strong 
association between negatively-charged DNA and the positively-charged histones.  
Acetylation neutralizes the charge on lysine residues within the histone tail, weakening 
the DNA-histone association and allowing the binding of transcription machinery.  
Deacetylation restabilizes this interaction.  Acetyl-lysine residues may serve as a signal 
for transcriptional regulators and removal of this signal by deacetylation might impair the 
assembly or recruitment of transcriptional activators [22].   
Deacetylation specific factors can inhibit RNA Polymerase I-dependent 
transcription, suggesting that transcription machinery may be directly targeted [21].  
Acetylation of sequence-specific transcriptional activators has been found to alter their 
DNA-binding ability, activation potential, stability, nuclear localization and coactivator 
interaction.  Histone deacetylation neutralizes these effects.  Histone deacetylation 
removes acetyl groups and thereby promotes the association of silencers [21]. 
 
1.2.6 Transcriptional Repression 
Maintenance and de novo DNA methylation are associated with the silencing of 
gene expression through direct and indirect mechanisms.  DNA-binding proteins can 
directly target DNMTs to promoter regions, introducing hypermethylation and repressing 
transcription.  For example, the PML-RAR fusion protein induces gene hypermethylation 
and silencing by recruiting DNMT1 and DNMT3a to target the RARβ2 promoter [9].  
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Indirect mechanisms involve the binding of methyl-CpG-binding proteins to methylated 
promoters.  Methyl-CpG-binding proteins can compete with or displace other DNA-
binding proteins and repress transcription of methylated promoters.  A methyl-CpG-
binding protein can repress transcription through the recruitment of histone-modifying 
complexes to methylated cytosines, which induces the formation of compact chromatin 
and renders the locus less accessible to necessary transcription factors [6] (Figure 1.1).  
Methyl-CpG-binding protein MeCP2 and methyl-CpG-binding domain proteins MBD2 
and MBD3 contain histone deacetylases HDAC1 and HDAC2 and other transcriptional 
co-repressors.  MBD3 also resides in a complex with Mi2, a chromatin remodelling 
protein.  Therefore, methyl-CpG-binding proteins serve as a bridge between the two 
major epigenetic mechanisms, DNA methylation and histone modification [17]. 
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Figure 1.1 Schematic of epigenetic gene silencing. 
 
The promoters of most actively transcribed genes may be occupied by both 
activating and repressing protein complexes.  Gene expression levels are then determined 
by cellular signals influencing the amount of these complexes and post-translational 
modifications of proteins in these complexes [8].  
The possibility that DNA methylation patterns might be controlled by the 
methylation status of histones emerged from genetic studies.  A gene of Arabidopsis, 
Kryptonite, is required for the maintenance of CpG methylation at silenced reporter 
constructs and also encodes a histone methyltransferase [20].  It is possible to replace the 
acetyl group at H3 Lys9 with one to three methyl groups.  This was shown to be essential 
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for DNA methylation in fungus, suggesting that histone methylation may provide a signal 
for DNA methylation [7].  Also, mutations in a putative histone methyltransferase result 
in loss of CpG methylation, suggesting that histone methylation precedes DNA 
methylation [18]. 
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DNMT DNMT 
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Transcription 
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TSA DNMT 
Demethylase 
SAM 
Ac Ac Ac Ac Ac Ac Ac Ac Ac Ac 
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HDAC 
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Figure 1.2 Schematic of DNMT, HDAC and DNA demethylase inhibition. 
 
Evidence shows that pre-treatment of cells with DNMT inhibiting agents allows 
greater reactivation of silenced genes by treatment with histone deacetylase inhibitors 
(Figure 1.2).  These results indicate that DNA methylation works in concert with methyl-
CpG-binding proteins and histone deacetylases in epigenetic transcriptional silencing of 
genes [8].  Since DNA methyl-CpG-binding domain proteins and DNMT1 recruit 
HDACs to methylated promoters and MBD-containing corepressors associate with 
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methylated CpG islands, it has been suggested that histone acetylation is secondary to 
DNA methylation [18].   
 
1.2.7 DNA Methylation and Tumourigenesis 
Point mutations, deletions and insertions are present throughout the genome of a 
neoplastic cell.  However, a malignant cell has also acquired a different epigenotype [5].  
Epigenetically mediated loss of gene function precedes and appears to be essential for 
several genetic events that drive tumour progression [8]. 
A normal cell has to acquire several novel capabilities in order to become a bona 
fide cancer cell: limitless replicative potential, self-sufficiency in growth signals, 
insensitivity to growth-inhibitory signals, evasion of programmed cell death, sustained 
angiogenesis and tissue invasion and metastasis [16].  A cancer cell acquires its unique 
characteristics through a stepwise accumulation of heritable changes in the content of 
proto-oncogenes, tumour suppressor genes, metastasis-promoting genes and metastasis 
suppressor genes.  While gain, loss and mutation of genetic information commonly 
contribute to tumourigenesis, epigenetic mechanisms play an equally important role.  
Methylation of CpG islands in promoter regions of tumour suppressor genes lead to 
transcriptional silencing via histone deacetylation and chromatin remodelling, 
representing a tumourigenic event functionally equivalent to genetic changes like 
mutation and deletion.  The two alleles of a tumour suppressor gene may be inactivated 
by any combination of genetic and epigenetic events [13]. 
The process of CpG hypermethylation is probably progressive, consisting of 
several steps of deregulated methylation.  Cancer methylation may spread from normal 
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methylation centers surrounding the methylation-free CpG island.  Certain CpG 
dinucleotides may become methylated as a result of basal methylation, creating a focus 
for further methylation [5].  Normally unmethylated CpG islands may become 
methylated in cancer cells [18].  This may occur if hypermethylation confers a selective 
advantage for the survival of that particular cancer cell [5].  DNA hypermethylation 
events may cause the inactivation of genes involved in the cellular response to 
chemotherapy, inactivation of ‘caretaker’ genes such as those involved in DNA repair 
and protecting cells from carcinogenic agents [13].   
Loss of cell cycle control resulting in unrestrained cell proliferation is a classic 
event in tumourigenesis.  Increased cell proliferation may required for epigenetic changes 
in cancer cells, since CpG islands are not remethylated in non-dividing cells suggesting 
that de novo CpG island methylation occurs only in dividing cells.  Overexpression of 
DNMTs in normal cells can produce aberrant de novo methylation of CpG islands and 
promote cellular transformation.  DNMT mRNA levels are regulated during the cell 
cycle.  Improper DNMT expression during the cell cycle can contribute to methylation 
alterations in cancer cells.  Hypermethylated CpG islands leave molecular footprints from 
which the event of epigenetic progression can be reconstructed during tumourigenesis 
[18]. 
Many cancer-related genes harbour dense methylation in normally unmethylated 
promoter CpG islands, which affects most cellular pathways with many consequences [8] 
[14].  For example, genes involved in DNA repair (MGMT), drug resistance, cell cycle 
regulation (p16INK4a, p15INK4b, p14ARF), growth, differentiation, apoptosis (DAPK), 
signalling, hormonal regulation (RARβ2), angiogenesis, cell adherence (CDH1), 
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metastasis and invasion, are associated with methylation-regulated gene silencing in 
different tumour types [15] [12] [5].     
The DAPK gene was isolated as a positive mediator of interferon-γ-induced 
apoptosis.  It also has a role in the activation of a p19ARF/p53 cell cycle checkpoint.  
The loss of DAPK expression or methylation of its associated CpG island may 
characterize highly invasive or metastatic tumours.  Therefore, methylation or loss of 
expression could be associated with a metastatic phenotype [15]. 
Hypermethylation of the cell-cycle inhibitor gene, p16INK4a, enables cancer cells 
to escape senescence and begin to proliferate [14].  p53 is inactivated through 
methylation-mediated silencing of the tumour suppressor gene p14ARF, which normally 
inhibits MDM2, an oncogenic protein that induces p53 degradation.  p73, a p53 
homologue, is shown to be hypermethylated in leukemia [14].  DNA methylation affects 
repair pathways by silencing DNA mismatch repair genes, hypermethylation of mitotic 
checkpoint genes and preventing repair of DNA double-strand breaks [14]. 
In cancer, promoter hypermethylation is often associated with wide spread loss of 
methylation throughout the genome and modest increases in expression of all three DNA 
methyltransferases [16].  DNA from breast carcinomas is generally hypomethylated.  
Global hypomethylation contributes to carcinogenesis through chromosomal instability, 
reactivation of transposable elements and loss of imprinting [14] [13].  
It appears that some genes are predisposed to CpG island hypermethylation.  
Genes with the highest incidence of dense promoter hypermethylation in colon cancer 
appear predisposed to this change by aging.  Promoter CpG islands of these genes are 
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slightly methylated in the normal colon of young individuals.  The density of methylation 
increases with age and is highest in cancer [8]. 
Epigenetic alterations are among the most common molecular alterations in 
human neoplasia, resulting in a revision of Knudson’s two-hit hypothesis.  In addition to 
the traditional two possibilities: loss of heterozygosity or homozygous deletion, a third 
possibility can disable tumour suppressor genes: epigenetic silencing by DNA 
methylation and histone deacetylation within promoter regions [16]. 
 
1.3 Metastasis Suppressor Genes 
Metastasis suppressor genes are defined as genes responsible for suppressing 
metastasis without affecting primary tumour growth [4].  Restoration of metastatic 
suppressor gene expression would yield cells that are still tumourigenic but are no longer 
metastatic.  On the other hand, tumour suppressor genes suppress primary tumour growth 
and, by default, suppress metastasis.  Metastasis genes can be identified through 
comparison of cell lines different in metastatic potential.  Differential display, subtractive 
hybridization and microarray technologies are all methods of measuring differential gene 
expression.  Identification of metastasis suppressors is much less complicated than of 
metastasis-promoting genes, since many genes are required for the progression of 
metastasis but the expression of only a single novel gene may suppress this progression 
[4].   
There are several examples whereby the expression of metastasis suppressor 
genes is lost, not through conventional mutations, but via alternative epigenetic 
mechanisms for loss-of-function [4].  Prostatin is a serine protease that decreases 
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invasiveness in vitro.  Both prostatin mRNA and protein are detected in normal breast 
cells, poorly invasive and nonmetastatic breast carcinoma cell lines but are not detected 
in highly invasive or metastatic breast carcinoma cells.  Demethylation coupled with 
histone deacetylase inhibition mediated the reactivation of prostatin gene expression in 
highly invasive, metastatic cell lines.  Induced expression resulted in a 50% reduction of 
in vitro invasiveness of these cells [16]. 
At least eight metastasis suppressor genes have been identified that show 
involvement in breast cancer progression [4].  The first of these is E-cadherin, which is a 
calcium-dependent mediator of cell-cell interactions [4].  Invasion and metastasis 
involves changes in the physical coupling of cells to their microenvironment and 
activation of extracellular processes.  Epithelial cells maintain contact with their 
neighbours through adherens junctions.  Cadherins traverse the membrane, associating 
with cadherins on adjacent cells [16].  Exogenous E-cadherin expression, via transfection, 
decreases motility and invasiveness.  High E-cadherin levels inhibit shedding of tumour 
cells from the primary tumour and thus, E-cadherin is considered a metastasis suppressor 
[3].  The E-cadherin gene (CDH1) is located on chromosome 16q22.1, a region 
associated with loss of heterozygosity in cancer.  However, gene loss may not solely be 
responsible for CDH1 loss-of-function.  Differential methylation patterns have been 
identified in the CpG islands of the CDH1 promoter regions.  In one study, promoter 
methylation was not evident in normal breast epithelium but was evident in some breast 
carcinomas.  Hypomethylation of the CDH1 promoter correlates with increased gene 
expression [4].  Direct involvement of hypermethylation in CDH1 gene suppression was 
supported by the observation that its expression can be reactivated by DAC treatment [8]. 
 19
Tissue inhibitors of metalloproteinases (TIMPs) inhibit the activity of matrix 
proteinases by forming strong noncovalent complexes.  Decreased matrix proteinase 
activity results in less invasive cells and thus, inhibits metastasis [23].  TIMP-2 promoter 
hypermethylation was detected in several leukemia and lymphoma cell lines and is 
associated with transcriptional repression. Treatment with the demethylating agent DAC 
resulted in TIMP-2 upregulation in these cell lines [24].  
Nm23 was the first novel metastasis gene discovered.  The human gene, NME1, 
maps to chromosome 17q21 [4].  NME1 is a bona fide metastasis suppressor gene in 
human breast carcinoma since transfection of metastatic MDA-MD-435 cells with NME1 
suppressed metastasis [3].  Expression of NME1 was down-regulated in late-stage, 
metastatic breast, endometrial, ovarian, melanoma and colon cancer.  NME1 promoter 
hypomethylation was associated with increased expression, suggesting epigenetic 
mechanisms may regulate this gene [4].  The nm23 gene family exhibits metastasis 
suppressor activity in breast cancer in vivo.  Two CpG islands are present in the nm23-HI 
promoter.  Bisulfite sequencing of these CpG islands in a panel of cell lines and in 20 
infiltrating ductal carcinomas revealed that one island exhibited infrequent differential 
methylation.  Treatment with DAC increased the nm23-HI expression in 5 of 11 human 
breast carcinoma cell lines in vitro, including all three metastatically competent cell lines.  
Increased nm23-HI expression was accompanied by a reduction in motility in vitro, with 
minimal effect on proliferation [16]. 
Maspin is a member of the serpin family of serine protease inhibitors and is 
located on chromosome 18q21.3-q23.  In one study, six of seven mammary carcinoma 
cells lines that did not express maspin exhibited aberrant methylation of the maspin 
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promoter.  Maspin expression can be restored in these cell lines by treatment with the 
hypomethylating agent, DAC [25]. 
Kai1 encodes an adhesion molecule that maps to chromosome 11p11.2, a region 
commonly associated with breast cancer progression [2].  Transfection of Kai1 into 
MDA-MB-435 cells suppressed metastasis from the mammary fat pad [3].  Kai1 
expression inversely correlates with aggressive behaviour in breast cell lines.  Survival of 
patients with Kai1-negative tumours is significantly lower than of those with Kai1-
positive tumours.  As with NME1 and maspin, the Kai1 promoter exhibits aberrant 
methylation patterns [26]. 
KiSS1 is located on chromosome 1q32.  Studies have shown an inverse 
correlation of KiSS1 expression with melanoma metastatic potential [4].  KiSS1 
expression is lost as melanoma cells convert from radial to vertical growth phase (benign 
to malignant transformation).  Transfection of KiSS1 into MDA-MD-435, which has no 
endogenous KiSS1 expression, resulted in suppression of metastasis from the mammary 
fat pad of athymic mice [3].   
Introduction of a portion of chromosome 17 significantly suppresses the 
metastatic ability of rat prostate AT6.1 cancer cells.  MKK4 was identified in this region.  
Transfection of a MKK4/SEK1 expression construct into AT6.1 significantly suppressed 
metastasis without affecting primary tumour growth [3].  Studies on KiSS1 and MKK4 
revealed that tumour cells defective for these two genes are able to complete every step 
of the metastatic cascade except growth at the secondary site, implying that these genes 
are metastasis suppressors [4]. 
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The breast cancer metastasis suppressor 1 (BRMS1) gene is located on 
chromosome 11q13.1-13.2, a region commonly altered in late-stage breast carcinomas 
[2].  Transfection of BRMS1 into MDA-MB-435 and MDA-MB-231 breast carcinoma 
cell lines suppressed metastasis without affecting tumourigenicity [3].  The BRMS1 
protein is located in the nucleus, contains a glutamate-rich domain, an imperfect leucine 
zipper and coiled-coil domains, suggesting that it may be part of a transcription complex 
[4].  BRMS1 suppresses metastasis of multiple human and murine cancer cells without 
inhibiting tumourigenicity.  It was found to interact with retinoblastoma binding protein 1 
and seven members of the HDAC complex using yeast two-hybrid and co-
immunoprecipitation techniques.  BRMS1 was shown to be a component of an HDAC 
complex, contributing to transcriptional repression [27]. 
 
1.4 Relevance 
While genetic mutations confer a fixed irreversible state of gene inactivation, 
epigenetic events do not interfere with the information content of the affected genes and 
are potentially reversible.  Epigenetic silencing can be alleviated by two mechanisms: 
inhibition of DNA methylation and inhibition of histone deacetylation [13].  However, 
drugs used to inhibit DNMTs can also cause global hypomethylation.  Lower doses of 
DAC combined with inhibitors of histone deacetylases such as TSA, depsipeptide, 
suberoylanilide hydroxamic acid and sodium butyrate may reactivate epigenetically 
silenced genes [14].  TSA was one of the first HDAC inhibitors identified as an anti-
proliferative agent, and although it has never progressed as a clinical candidate, it has 
been a valuable tool in validating HDAC enzymes as potential anti-cancer targets [10].   
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A promising clinical scenario for the use of epigenetic therapy is acute 
promyelocytic leukemia (APL), which is caused by transcriptional disruption induced by 
the PML-RARα translocation.  Inhibitors of histone deacetylases, inhibitors of DNA 
methylation and differentiating factors have achieved success in APL patients [14].  
Inhibitors of class I/II HDACs and DNMTs are currently in clinical trials for cancer 
treatment.  Research on these enzymes may improve the therapeutic potential of 
deacetylase and DNMT inhibitors in ‘transcription therapy’ of human diseases, including 
cancer [21].   
CpG islands are mostly unmethylated in normal tissues but are methylated to 
varying degrees in human cancers, including breast cancer [16].  DNA methylation serves 
as a more useful tumour biomarker compared to other DNA alterations because there are 
usually no interindividual variations in the methylation pattern of a particular gene.  The 
use of DNA methylation as a marker allows the establishment of highly sensitive and 
universally applicable assays via methylation-specific PCR.  A novel microarray 
technique, differential methylation hybridization (DMH), allows for global analysis of 
DNA methylation in cancer.  In ovarian cancer, this approach has revealed tumour groups 
with distinct methylation patterns that respond differently to chemotherapy.  The use of 
expressed CpG island sequence tags (ECISTs) has further refined DMH.  GC-rich 
regions of ECISTs are used to screen for methylated CpG sites in cancer cells and exon-
containing fragments of ECISTs are used to measure levels of gene expression [18].  
Tumour-specific DNA is easily obtained from sputum of lung cancer patients, urine from 
prostate cancer patients and serum of cancer patients to facilitate DMH screening [13]. 
 23
Promoter hypermethylation of CpG islands in tumour suppressor genes occurs 
early in tumourigenesis, implicating the possibility of early detection in cancer via DMH 
screening [14].  Promoter hypermethylation is frequently associated with BRCA1 
silencing in non-inherited breast and ovarian carcinomas [8].  Therefore, a DNA-based 
approach to screening for breast cancer may complement the current mammography-
based approach [16].   
Genes that are inactivated by promoter hypermethylation can be used as 
prognostic factors.  Methylation-associated silencing affects many genes in most cellular 
pathways.  Hypermethylation of DAPK and p16INK4a have been linked with poor 
prognosis in colorectal cancer.  Other possible aberrantly methylated genes awaiting 
analysis for their relation to metastatic or angiogenic activity in primary tumours include 
those encoding E-cadherin, H-cadherin and thrombospondin 1 [14]. 
Products of genes that are silenced by DNA methylation can be used as 
biomarkers of response to therapy. The lack of effectiveness of antisteroidal drugs is a 
consequence of methylation-mediated silencing of their respective cellular receptors.  
Premalignant lesions become insensitive to retinoids because of epigenetic silencing of 
genes that are crucial to the retinoid response, particularly the retinoic acid receptor.  The 
DNA repair gene MGMT, encoding protein O6-methylguanine-DNA methyltransferase, 
undergoes transcriptional repression as a result of methylation-associated silencing.  
MGMT is responsible for repairing the addition of alkyl groups to guanine.  Tumours that 
lost MGMT due to hypermethylation would be more sensitive to the action of alkylating 
agents since their DNA lesions could not be repaired in the cancer cell [5].  Although 
silencing of this gene alone is a poor prognostic factor because patients acquire more 
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mutations, hypermethylation of this enzyme’s promoter was indicative of a good 
response to chemotherapy, greater overall survival and longer time in remission [14]. 
Hypermethylation of CpG islands occurs in conjunction with the action of 
methyl-CpG-binding proteins, histone hypoacetylation and histone methylation, which all 
contribute to formation of a closed chromatin state and transcriptional silencing.  Several 
pharmaceutical and biotechnology companies are using novel approaches such as 
antisense constructs, ribozymes and RNA interference to target these elements of the 
methylation machinery.  Some companies are investigating the use of gene-therapy-like 
strategies to reactivate specific methylated genes [14]. 
Chemoresistance is a major hindrance of effective chemotherapy.  There are 
several cellular and molecular mechanisms resulting in chemoresistance.  The expression 
of genes conferring chemoresistance can be reversibly turned off by DNA methylation.  
Chemotherapy destroys cancer cells by inducing apoptosis, or programmed cell death.  
Deregulation of genes involved in the activation or execution of apoptosis may serve as a 
mechanism for chemoresistance.  For example, loss of caspase-8 expression, an 
apoptosis-related protein, resulted in resistance to cytotoxic drugs like doxorubicin and 
cisplatin.  Treatment of cells containing caspase-8 promoter hypermethylation with a 
demethylating agent led to re-expression of caspase-8 and restored chemosensitivity [13]. 
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1.5 Introduction to MS-1 
 
1.5.1 R3230AC Model System 
 A rat mammary adenocarcinoma cell line was used to isolate two subpopulations 
differing in metastatic phenotype in order to investigate properties unique to these 
populations.  The poorly metastasizing R3230AC rat mammary adenocarcinoma was 
cyclically enriched for metastasizing cells to derive the highly metastatic LN4 
subpopulation [28].  Briefly, female Fischer 344 rats were injected with 106 R3230AC 
cells in the hind footpad, which is drained by the popliteal lymph node.  These cells 
metastasize initially through the lymphatic system making this a good model for many 
human tumours, such as breast cancer, which metastasize initially through the 
lymphatics.  Infrequent lymph node metastases (10% of injected animals showed 
evidence of metastases) were excised, the tumour cells grown in culture and subsequently 
reinjected into another series of rats.  The proportion of animals bearing lymph node 
metastases progressively increased with sequential enrichments.  After three (LN3) or 
four (LN4) enrichments, the frequency of lymphatic metastasis increased to 100% of 
injected animals [28]. 
An increased percentage of cells binding high levels of the lectin soybean 
agglutinin (SBA) was observed with each enrichment cycle, and showed a strong 
correlation with the metastatic potential of these cell populations [28].  The SBA binding 
component on the surface of these cells was found to be a neutral glycosphingolipid, 
identified as isoglobotetraosylceramide (iGb4Cer) [29] [30].  An R3230AC-LG3 cell line, 
enriched for lung colony formation, also showed enrichment for iGb4Cer expression [30].  
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Depletion of the subpopulation of cells containing this cell surface marker within the 
R3230AC-LN4 cell line by antibody-dependent complement-mediated cytolysis using the 
anti-iGb4Cer monoclonal antibody 3E9 resulted in a cell population (CAb) with a 
substantially decreased metastatic potential without significantly altering the primary 
tumour growth rate [29].  Similarly, depletion of iGb4Cer expressing cells within the 
R3230AC-LG3 cell line with antibody-dependent complement-mediated cytolysis 
significantly reduced lung colony formation [30].  Blocking the iGb4Cer on the surface of 
LG3 cells with the monoclonal antibody 3E9 or its Fab fragments greatly decreased lung 
colony formation, suggesting it may play a direct role in the metastatic process [30]. 
 
1.5.2 MS-1 Identification and Differential Expression 
The LN4 and CAb subpopulations of our model system have many similar 
characteristics, such as tumourigenicity, but allow for the identification of genes that are 
differentially expressed and that may be involved in generating the metastatic phenotype.  
The production of iGb4Cer in metastatic cells was found to be associated with the loss of 
the sialyltransferase enzyme GM3 synthase, which competes for a common intermediate 
in iGb4Cer biosynthesis [31].  GM3 synthase was expressed in CAb cells but not in the 
iGb4Cer-producing LN4 cell line.  During attempts to isolate the GM3 synthase cDNA, 
genes differentially expressed between the CAb and LN4 cells were isolated.  A unique 1 
kb sequence was isolated that hybridized to a 2.8 kb mRNA in the CAb subpopulation 
but was undetectable in metastatic LN4 cells (Figure 1.3).  This mRNA was distinct from 
the reported rat GM3 synthase cDNA [32].  This differentially expressed novel gene was 
termed MS-1 [33] [34].  The relationship between metastatic phenotype and expression of 
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rat MS-1 (rMS-1) was also seen in a Dunning rat prostate adenocarcinoma system (Figure 
1.3).  The poorly metastatic AT1 subpopulation showed high levels of rMS-1 while there 
was no detectable rMS-1 expression in malignant MAT-LyLu cells [33].  
 
  
rMS-1 
GAPDH 
LN4 CAb 
2.7 kb 
MAT-LyLu AT1 
 
Figure 1.3 Northern analysis demonstrating the differential expression of rMS-1.   
A total of 10 μg of total RNA was loaded in each lane, transferred and probed with a 565 
bp rMS-1 specific cDNA probe or 452 bp GAPD rat specific cDNA probe. (n>2) 
 
 
  The observation that MS-1 expression varied in a number of rat cell lines led to 
cloning and characterization of a human homologue of rMS-1.  Northern analysis was 
used to screen human breast tumour cell lines for MS-1 expression (Figure 1.4).  
Hs578Bst, Hs578T and WiDr cells were positive for MS-1 expression, MDA-MB-231 
cells were weakly positive for MS-1 expression, while MCF-7, MDA-MB-435, T-47D, 
HEY, SW480 and SW620 cells were negative [34].  The information provided by ATCC 
indicates that MDA-MB-231, MDA-MB-435, MCF-7 and T-47D were cell lines derived 
from pleural effusion samples from female patients with advanced breast cancer.  The 
SW480 cell line was established from a primary adenocarcinoma of the colon and the 
SW620 cell line was established from a lymph node metastasis taken from the same 
patient one year later.  The WiDr cell line was established from a colon adenocarcinoma.  
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The malignant ovarian epithelial cell line, HEY, was established from a human ovarian 
carcinoma.  Hs578T cells were recovered from a primary tumour of a breast cancer 
patient and the Hs578Bst cell line was established from normal tissue peripheral to this 
tumour.  The majority of these results support our previous observation that MS-1 
expression is limited to cells of low metastatic potential. 
 
W
iD
r 
hMS-1
GAPDH
2.4 kb 
H
s5
78
B
st
 
H
s5
78
T 
M
D
A
-M
B
-2
31
 
M
D
A
-M
B
-4
35
 
T
-4
7D
 
M
C
F-
7 
W
iD
r 
H
E
Y
 
SW
62
0 
SW
48
0 
Figure 1.4 Northern analysis demonstrating the differential expression of hMS-1.   
A total of 15µg total RNA was loaded in each lane, transferred and probed with a 558 bp 
hMS-1 cDNA specific probe or 452 bp GAPD human specific cDNA probe. (n>2) 
 
1.5.3 Old Astrocyte Specifically Induced Substance (OASIS) 
The murine homologue of MS-1, OASIS (Old Astrocyte Specifically Induced 
Substance), was identified and characterized [35].  It was specifically induced in long-
term cultured mouse astrocytes, an in vitro model of gliosis.  Gliosis, the injury response 
of astrocytes in the central nervous system, is characterized by the phenotypic 
modification, proliferation and migration of reactive astrocytes [36].  OASIS expression 
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was induced in gliotic tissues following cryo-injury of the cerebral cortex or spinal cord 
injury, suggesting it may play a role in gliotic events [35] [37]. 
OASIS was strongly expressed in embryonic tissues including salivary gland, 
tooth germs, bone and cartilage [35] [37].  OASIS showed transient upregulation in the 
mouse brain during the two weeks postnatal and weaker expression in the adult, 
suggesting it to be a developmentally regulated gene [35].  Other suggested roles include 
involvement in osteogenesis, as OASIS expression overlapped several osteogenesis 
markers.  Expression patterns of OASIS throughout development of bone and cartilage 
were similar to expression of the gene encoding X-box binding protein, XBP1, another 
basic leucine zipper (bZIP) transcription factor [37]. 
It was shown by Nikaido et al. that the OASIS protein could specifically bind the 
cAMP response element (CRE) consensus sequence, consistent with other CREB family 
members [38].  A transcriptional activation domain was identified at the amino-terminus 
of OASIS [37] [39].  Fusion proteins with the Gal4 DNA binding domain and OASIS 
were able to activate transcription of luciferase reporter constructs.  The minimum region 
of CREB3L1 required for this transcriptional activation was identified between amino 
acids 1 and 60 [39]. 
 
1.5.4 Role of MS-1 
The evolutionary conservation of MS-1 illustrated by sequence homology 
between the human, rat and mouse genomes implies a functional requirement.  The 
widespread expression of MS-1 in tissues of all three species, including embryonic 
tissues, suggests that it is a normally expressed factor that may be involved in 
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development.  Expression profiles of OASIS suggest roles in gliosis, salivary gland 
development and osteogenesis. 
The MS-1 protein contains a transactivation domain, basic region, leucine zipper 
and transmembrane domain.  Immunofluorescence analysis determined the subcellular 
localization of MS-1 to be within the cytosol in the vicinity of Rhodamine B-stained 
endoplasmic reticulum (ER).  Truncation of the carboxy-terminus, which contains the 
transmembrane domain, altered localization to the nucleus in addition to the cytosol [34].  
MS-1 is a novel CREB/ATF family transcription factor that seems to be involved in 
signal transduction from the ER to the nucleus.  Studies indicate MS-1 is cleaved by 
regulated intramembrane proteolysis (RIP), producing the truncated, active MS-1 
transcription factor [34].  RIP is a process that allows cells to respond quickly to 
physiological crises by activating pre-made transcription factors [40].  MS-1 undergoes 
RIP following treatment with chemical inducers of ER stress [34].   
Studies on OASIS reveal that the protein is cleaved in response to ER stress and 
that mutations at site-1 and site-2 protease sites prevents this cleavage.  Also, OASIS 
mRNA is induced in astrocytes following treatment with various ER stressors.  OASIS 
has been characterized as an ER-stress transducer for the unfolded protein response 
(UPR).  Endogenous OASIS binds to CRE and ER response element (ERSE) sequences 
within the BiP promoter, inducing its expression, in response to ER stress.  BiP is a UPR 
target gene that functions as a cytoprotective protein in stress cells.  It was proposed that 
OASIS could protect cells from ER stress.  Studies showed that OASIS-transfected cells 
had a higher resistance to ER stress-induced cell death and that knockdown of OASIS 
expression caused cells to undergo apoptosis [40].   
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The inverse relationship between the metastatic phenotype and MS-1 expression 
presents the possibility that the MS-1 protein may have a role in suppressing metastasis.  
As primary tumours grow in size, the cancer cells experience hypoxia, nutrient starvation 
and acidosis, which hinders cell proliferation and can result in cell death [41].  Cells may 
adapt to this ischemic environment by producing pro-angiogenic factors that initiate the 
formation of new blood vessels to the tumour, and allow the tumour cells to enter the 
bloodstream and metastasize.  However, conditions within the tumour microenvironment 
also result in ER stress and gene expression changes through the UPR signalling pathway 
[41].  ER stress results in RIP cleavage of MS-1, which was shown to induce BiP 
expression and protect cells from ER stress-induced apoptosis.  Therefore, it is possible 
that MS-1 protects primary tumour cells from undergoing apoptosis, even under ischemic 
conditions, eliminating both the requirement for angiogenesis and the opportunity for 
metastasis.  In the absence of MS-1 there would be no induction of BiP and thus, no 
protection from ER stress-induced apoptosis.  Tumour cells lacking MS-1 expression 
would require angiogenesis for survival.  It has been shown that following nutrient 
deprivation, hypoxia and ER stress, pro-angiogenic factors are induced in metastatic 
breast cancer cell lines MCF-7 and T-47D, which do not express MS-1 [41]. 
If MS-1 is shown to be involved in suppressing metastasis, it may play future 
roles as a marker for diagnosis and in the treatment of metastatic breast cancer. 
 
1.6 Objectives 
The study of epigenetic gene regulation has presented a relatively novel model for 
understanding the control of gene expression in the progression of various diseases, 
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including cancer metastasis.  A number of genes appear to inhibit the metastatic process.  
Such genes are commonly identified on the basis that they are lost or down regulated 
during the progression of metastasis.  The discovery of a novel gene, MS-1, whose 
expression appears limited to cells of low metastatic potential, led to the suggestion that 
this gene may play a role in metastasis.  The presence of a CpG island in the 5’ region of 
MS-1 promoted an investigation of epigenetic silencing of MS-1 in highly metastatic 
cells.  The purpose of the following research was to investigate the mechanism by which 
MS-1 expression is down regulated in cells of high metastatic potential.  This research 
identified different methylation profiles of the MS-1 CpG island in cells of different 
metastatic potential.  It also uncovered possible mechanisms by which this methylation 
profile may be altered via reversal of epigenetic silencing mechanisms.  This evidence 
presents a novel application for demethylating agents, which are currently in clinical 
trials, and provides reasoning to further research on epigenetic therapy as a possibility in 
cancer treatment. 
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2.0 MATERIALS AND METHODS 
 
2.1 Materials 
 
2.1.1 Cell Lines 
LN4.D6 is a clone of the highly metastatic LN4 subpopulation of the rat mammary 
adenocarcinoma R3230AC, selected by cyclic enrichment of increased metastatic ability 
[28]. These cells were found to specifically express high levels of the neutral glycolipid, 
isoglobotetraosylceramide.  CAb.D5 is a clone selected from the poorly metastatic 
subpopulation (CAb), which was selected from the highly metastatic LN4 subpopulation 
by depletion of cells expressing this glycolipid marker by treatment with complement and 
antibody against this glycolipid surface marker [29].  
Both AT1 and MAT-LyLu sublines were derived from the original spontaneous 
dorsal prostatic adenocarcinoma tumour R3327 initially discovered in 1961 by W.F. 
Dunning in a 22-month-old inbred Copenhagen male rat [42].  The AT1 subline was 
serially passaged and rarely produced distant metastases [43].  MAT-LyLu is the 
metastatic subline derived from successive in vivo passages of the AT1 tumour [44].  
MAT-LyLu readily formed metastases in the lymph nodes and the lungs.  Both cell lines 
were obtained from the European Collection of Cell Cultures. 
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Hs578T cells were derived from a human breast carcinoma.  The Hs578Bst cell 
line was established from normal tissue peripheral to this tumour [45].  MDA-MB-231, 
MDA-MB-435, T-47D, and MCF-7 cell lines were isolated from the pleural effusions of 
patients with breast carcinoma [46] [47] [48].  All human breast cancer cells were 
obtained from the American Type Culture Collection (ATCC) except MDA-MB-435 
cells, which were kindly supplied by Dr. J. Price (MD Anderson Cancer Center, Texas).  
The SW480 cell line was established from a primary adenocarcinoma of the colon and 
the SW620 cell line was established from a lymph node metastasis taken from the same 
patient one year later.  The WiDr cell line was established from a colon adenocarcinoma.  
SW480, SW620 and WiDr cell lines were kindly supplied by Dr. K. Bonham (Saskatoon 
Cancer Centre).  The malignant ovarian epithelial cell line, HEY, was established from a 
human ovarian carcinoma and kindly provided by Dr. R. Hickie (University of 
Saskatchewan).   
 
2.1.2 Bacterial Strains and Growth Conditions 
Escherichia coli (E. coli) strain INVαF’ [F’ endA1 recA1 hsdR17 (rk-, mk+) 
supE44 thi-1 gyrA96 relA1 Φ80lacZΔM15 Δ(lacZYA-argF)U169 λ-] (Invitrogen) was 
grown in Luria-Bertani Broth (LB, Difco laboratories) containing 1.0% (w/v) bacto-
tryptone, 0.5% (w/v) bacto-yeast extract and 1.0% (w/v) NaCl pH 7.0.  The LB 
ingredients were dissolved in deionized water and autoclaved for 20 min at 120ºC.  For 
selective growth of transformed bacteria 100 μg/mL of ampicillin was added and all 
cultures were grown at 37°C while shaking at 300 rpm. 
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2.1.3 Plasmids 
The plasmid pCR2.1 (Invitrogen) was used for direct cloning and sequencing of 
PCR purified amplifications of either rMS-1 or hMS-1 CpG islands.  
 
2.1.4 Reagents and Supplies  
All chemicals and enzymes used were of analytical grade or higher, and were 
purchased from BDH, Sigma, or VWR unless otherwise stated. 
 
2.2 Methods 
 
2.2.1 Tissue Culture Media and Techniques 
Rat cell lines LN4.D6, CAb.D5, MAT-LyLu and AT1 were cultured in RPMI 
1640 (Invitrogen) supplemented with 10% bovine calf serum (BCS, HyClone 
Laboratories, Logan, Utah, U.S.A), 100 U/mL penicillin, and 100 μg/mL streptomycin.   
MAT-LyLu and AT1 media was supplemented with 2 mM L-glutamine, and 250 μM 
dexamethasone.  All media for human cells contained 10 % fetal bovine serum (FBS, 
Cansera), 100 U/mL penicillin, and 100 μg/mL streptomycin.  Hs578Bst cells were 
maintained in Hybri-care medium (ATCC) with 30 ng/mL epidermal growth factor.  
MCF-7 cells were grown in alpha-minimal essential medium (α-MEM, Invitrogen).  
SW480 and SW620 cells were maintained in Dulbecco’s modified eagles medium 
(DMEM, Invitrogen).  WiDr cells were grown in minimal essential medium (MEM, 
Invitrogen).  Hs578T, T-47D, MDA-MB-231, MDA-MB-435 and HEY cells were 
cultured in RPMI 1640 (Invitrogen).  Hs578T and T-47D media was supplemented with 
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0.2 U/mL Humulin-R insulin (Lilly), as well as 2 mM L-glutamine for Hs578T cells.  
Cultures were maintained at 37˚C with 5% CO2 and 100% relative humidity. 
To remove all adherent cells, the existing media was removed and cells were 
covered in a citrate saline (pH 7.8) solution containing 0.25% (w/v) trypsin (Gibco) for 
15-30 seconds before the excess solution was decanted.  A thin layer of trypsin solution 
was left on the cells until adequate dissociation was achieved.  To block the proteolytic 
action of the trypsin, an excess of media containing serum was added, the cells were 
resuspended and transferred to a 15 mL conical centrifuge tube for harvesting by 
centrifugation at 500 x g for 5 min.  Cell pellets were resuspended in complete media, 
and an aliquot of the cells was seeded into a new flask containing complete media. 
To appropriately store cells for later use, cells in a 175 cm2 flask of approximately 
70% confluence were harvested, as described above, and resuspended in 5 mL complete 
media with 10% (v/v) dimethyl sulfoxide (DMSO).  Approximately 1.5 mL of cell 
suspension was added to 1.8 mL Cryotube™ vials (NUNC Brand Products), and the 
tubes were immediately placed at –70°C, and if required, transferred to liquid nitrogen 
the next day. 
 
2.2.1.2 Drug Treatments 
CAb, LN4, Hs578T and MDA-MB-435 cells were grown to 60-70% confluence in 
10 cm2 plates with complete media and standard environmental conditions.  Cells were 
treated with either 1 μM 5-aza-2’-deoxycytidine (DAC) for 96 hours and/or 1 μM 
trichostatin A (TSA) for 3, 6, 12 or 24 hours, and incubated at standard environmental 
conditions.  Six day treatments with 100 μM S-adenosylmethionine (SAM) began at 20-
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30% confluency.  Cells were then removed from the plates, total RNA isolated and 
Northern analysis performed or genomic DNA isolated as described below. 
 
2.2.2 RNA Methods 
 
2.2.2.1 Total RNA Isolation 
Total RNA was isolated using an RNeasy Kit (Qiagen).  Cells were grown to 
approximately 80% confluency in complete media in a 15 cm2 plate as described above.  
The media was removed from the plate and the cells were rinsed with phosphate-buffered 
saline (PBS).  Cells were lysed directly in the culture dish in Buffer RLT, 4 mL for 
Qiagen’s RNeasy Midi Kit and 400 μL for Qiagen’s RNeasy Mini Kit.  Total RNA was 
isolated according to the manufacturer’s instructions for total RNA isolation from animal 
cells. 
RNA concentrations were determined by measuring the absorbance of the RNA 
samples at wavelength of 260 nm using a Pharmacia Biotech Ultraspec 3000 UV/Visible 
spectrophotometer.  Samples were stored at –70°C. 
 
2.2.2.2 Northern Gel Electrophoresis and Transfer 
A 1.2% agarose gel was prepared with 2.4 g agarose, 20 mL 10X MOPS solution 
(42% (w/v) 3-[N-Morpholino] propane sulfonic acid (MOPS), 0.05 M sodium acetate, pH 
7.0, 0.01M Ethylenediamine tetraactetic acid (EDTA)), 170 mL DEPC water and 10.8 
mL formaldehyde, and the gel was cast in a Model H5 Horizontal Gel Electrophoresis 
System stand (Life Technologies).  The samples for electrophoresis were prepared by 
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combining the appropriate quantity of RNA sample with Northern blotting buffer (48 % 
v/v formamide, 11% v/v 10X MOPS, 17% v/v 37% formaldehyde, 12% v/v DEPC water, 
7 % v/v 80% glycerol, 5% v/v 0.25% bromophenol blue solution) for a total volume of 30 
μL. Each sample was heated at 65°C for 1-2 min and placed on ice for an equivalent 
amount of time. 
The gel was run in 1X MOPS buffer for 3 hr at 70 V.  To confirm the presence 
and stability of the RNA, the gel was washed 6 times with distilled water for 5 min each 
and stained with 0.33 μg/mL ethidium bromide in distilled water for 5 min.  The ethidium 
stain was removed by 3 distilled water washes of 7-10 min each.  The RNA gel was then 
photographed before the markers were imprinted on the gel using Pelikan Drawing ink Z 
(Pelikan AG, Germany). 
The RNA was hydrolyzed for 15 min in 50 mM NaOH, followed by a 15 min 
rinse in distilled water, and neutralized in 100 mM Tris-HCl, pH 8.0 for 15 min. A final 
15 min rinse with distilled water was performed before membrane transfer.  Transfer to a 
positively charged nylon membrane (Gene Screen Plus, Perkin Elmer) was achieved 
using the sandwich setup [49]. The membrane and 3MM papers were soaked in 50 mM 
sodium phosphate, pH 6.7 prior to apparatus assembly.  The transfer was carried out 
overnight in the presence of excess 50 mM sodium phosphate, pH 6.7. 
The transfer apparatus was disassembled the following day, and the RNA size 
markers were impressed on the membrane for later reference.  The transferred RNA was 
permanently associated to the membrane by UV cross-linking with 1.2 x 105 μJoules (UV 
Stratalinker 2400).  The membrane was rinsed in 2 x SSC (300 mM NaCl, 30 mM 
sodium citrate) before being placed in a hybridization bag and stored at –20°C. 
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2.2.2.3 Northern Blot Hybridization 
Probes used for hybridization were amplified from either rat or human cDNA 
using standard PCR conditions (described below).  Table 1 outlines the primers and 
annealing temperatures specific for each cDNA probe.  Due to high sequence homology, 
the same primer set can be used to amplify the GAPDH probe from either rat or human 
cDNA.  To prepare a cDNA probe for Northern blot hybridization, 50 ng of double 
stranded cDNA was resuspended in TE (10 mM Tris HCl, pH 8.0, 1 mM EDTA) buffer 
to a final volume of 45 μL.  The DNA was denatured by heating it for 5 min at 95°C, and 
snap cooled on ice for 5 min.  The cDNA was added to the reaction tube (Amersham 
Biosciences RediprimeTM II Random Prime Labelling System) with 50 μCi α [32P]-dCTP, 
and mixed.  The reaction was incubated at 37°C for 10 min. 
The Northern membrane, as previously described, was thawed and rinsed in 0.5% 
SDS solution for 5 min.  Prehybridization of the membrane was performed by incubating 
in 20-30 mL Express-hyb solution (Clontech) for a minimum of 30 min at 68°C. 
The labelling reaction was stopped by adding 5 μL of 0.2 M EDTA to the 
reaction.  The dscDNA radiolabeled probe was denatured in a boiling water bath for 5 
min, snap cooled on ice for 5 min, and added to the hybridization tube containing 20-30 
mL of Express-Hyb solution.  The hybridization reaction was performed at 68°C for 17-
22 hr.  All hybridizations and subsequent washes were performed in a HYBAID Midi 
Oven (BIO/CAN Scientific). 
Membranes were washed 3 times in wash solution #1 [2X SSC, 0.05% sodium 
dodecyl sulfate (SDS)] for 5-10 min each at 68°C.  Each membrane was then washed 2 
times in wash solution #2 (0.1X SSC, 0.1% SDS) for 20 min each at 50°C.  Upon 
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completion, the membranes were exposed to an Imaging Screen K (Kodak) for use in a 
Molecular Imager FX phosphor imager (Bio-Rad).  The expression of MS-1 was 
standardized to the expression of a control, GAPDH, by densitometric analysis using 
Quantity One version 4.3.1 software. 
 
2.2.2.4 Northern Blot Stripping 
In order to probe a previously hybridized membrane, the cDNA probe was first 
removed by stripping the membrane.  Membranes were soaked in approximately 1 L of 
boiling stripping solution (0.1% SDS, 0.1X SSC) for 20-30 min followed by 5 min in 2X 
SSC at 60°C.  Membranes were exposed to autoradiographic film or phosphor imager 
screen for 2-18 hr to confirm successful removal of the previous cDNA radiolabelled 
probe.  Once adequate stripping was achieved, all membranes were stored at –20°C. 
 
2.2.3 DNA Methods 
 
2.2.3.1 Genomic DNA Isolation 
A QIAamp DNA Mini Kit (Qiagen) was used to extract genomic DNA from cells.  
A 175 cm2 flask of each cell line of interest was grown to confluence.  The cells were 
harvested as previously described and washed once with PBS.  They were resuspended in 
200 µL PBS and 20 µL of both RNase A and proteinase K was added.  The genomic 
DNA was extracted following the manufacturer’s instructions. 
The DNA concentrations were determined by measuring absorbance at 260 nm 
using a Pharmacia Biotech Ultraspec 3000 UV/Visible spectrophotometer. 
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2.2.3.2 Sodium Bisulfite Modification 
An EZ DNA Methylation Kit™ (Zymo Research) was used to sodium bisulfite 
modify isolated genomic DNA, following manufacturer’s instructions.  In brief, after 
genomic DNA isolation and purification, 2 µg of genomic DNA were treated with sodium 
bisulfite for 16 h.  After purification, a 2-µl aliquot was used as a template for PCR using 
ambiguous primers specific for neither methylated nor unmethylated DNA. 
   
2.2.3.3 PCR and Vector Construction 
Different primer sets were designed to amplify either the rMS-1 or hMS-1 CpG 
island from a genomic DNA template using polymerase chain reaction (PCR) (see Table 
2).  Generally, 2 μL of genomic DNA was mixed in a 50 μL reaction containing 200 nM 
of each primer, 0.8 mM dNTPs, 1X PCR buffer (Qiagen), and 2.5 units of either Taq 
DNA Polymerase (Qiagen) for untreated templates or HotStarTaq DNA Polymerase 
(Qiagen) for sodium bisulfite modified templates in thin-walled PCR tubes.  The contents 
were mixed thoroughly and placed into a thermocycler (Perkin-Elmer 2400).  Reactions 
containing untreated templates were denatured for 5 min at 96°C, followed by 35 cycles 
with a denaturation period of 1 min at 98°C, 30 seconds for annealing (See Table 1 for 
annealing temperatures), and a 72°C extension interval for 2 min.  Cycles were followed 
by a 7 min hold at 72°C and a final hold at 4ºC.  Reactions containing sodium bisulfite 
modified templates were denatured for 15 min at 96ºC, followed by the profile described 
above.  Nested PCR was performed using 2 μL of the primary PCR product as a template. 
To verify that the fragment of interest had been specifically amplified, the product 
was mixed with DNA running buffer (3.7 % (w/v) EDTA, 1% (w/v) SDS, 0.1% (w/v) 
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bromophenol blue, 4% (v/v) glycerol), then separated on a 1% TAE (24.2 % w/v Tris, 5.7 
% v/v glacial acetic acid, 0.05 M EDTA, pH 8.0) agarose gel along with a DNA marker 
(generally Fermentas 100 bp DNA step ladder or 1 kb marker).  The gel was stained with 
ethidium bromide to facilitate visualization of the DNA.  All DNA gels were run in 1X 
TAE buffer for 30-50 min at 90 V.  Agarose gels were photographed using a UV 
transilluminator/Gel documentation system (Bio-Rad). 
 
Table 2.1 PCR primers and annealing temperatures. 
Primer Name 
(annealing 
temp ˚C) 
Resulting Product 
(bp) 
Primer Sequence (5’ to 3’) 
SAC-223 
SAC-224 
(60) 
1º rMS-1 CpG58 
in untreated DNA 
(1345) 
TGGGGATTGGTGTCTTGTTAGTTC 
GGTTTACTTCAGGGTTTAGTGCC 
 
SAC-225 
SAC-226 
(59) 
Nested rMS-1 
CpG58 in 
untreated DNA 
(980) 
GAAGCCAGAGACCAATGTG 
GTTTCCAGGATAGTTTTGCC 
SAC-265 
SAC-266 
(51) 
1º rMS-1 CpG58 
in modified DNA 
(1263) 
TGGTGTATTTGATAGAGGTAAGGGG 
CRAAAACCCCCRACCCCTCCTTATC 
SAC-267 
SAC-257 
(48) 
Nested rMS-1 
CpG58 in 
modified DNA 
(995) 
CCTTGTGCTTTGTTCTGGTGCTGGGC 
TGCCAGGTGAGGGTCAGGTAGTCC 
SAC-131 
SAC-302 
(62) 
1º hMS-1 CpG51 
in untreated DNA 
(1202) 
GGAGACGCAGAGACAGAGGAGAG 
TAGGGAGAGGGAGAAAGTCAGC 
 
SAC-134 
SAC-303 
(63) 
Nested hMS-1 
CpG51 in 
untreated DNA 
(946) 
GAGGTGGAGTCGGCTGAATGC 
ATCACCCTATGTTGCCCTGACC 
 
SAC-304 
SAC-305 
(50) 
1º hMS-1 CpG51 
in modified DNA 
(960) 
AGTTGTGTTTTAGGAGGAGTAGG 
TTACCCTAACCRCCTCTTCC 
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SAC-306 
SAC-307 
(50) 
Nested hMS-1 
CpG51 in 
modified DNA 
(856) 
GTYGGTTGAATGTTTAYGGTG 
TCCCTAAAACTACCAAAATAACAC 
 
SAC-60 
SAC-68  
(59) 
rMS-1 cDNA 
probe (565) 
CTTGGGAGACCTGAATGAGTCG 
TGCTGGGGGGTGTTGGAGGCATC 
SAC-84 
SAC-85 
(63) 
hMS-1 cDNA 
probe (558) 
GCACTTTCCTGAGCACCTGGACCACTTTA 
TGGGAGCCGTCGCTGTCACTGC 
SAC-140 
SAC-141 
(58) 
GAPDH cDNA 
probe (452) 
ACCACAGTCCATGCCATCAC 
TCCACCACCCTGTTGCTGTA 
SAC-323 pCR2.1 
Sequencing 
(forward) 
GTAAAACGACGGCCAG 
SAC-324 pCR2.1 
Sequencing 
(reverse) 
CAGGAAACAGCTATGAC 
 
For future ligation into the pCR2.1 vector (Invitrogen), 2.5 units of Taq 
polymerase (Qiagen) was added to the reaction tube which was incubated at 37°C for 20 
min and 72°C for 20 min.  This resulted in the addition of dATP to the 3’ end of the PCR 
products for direct ligation into pCR2.1, which has a single 5’ thymidine overhang.  The 
fragment was ligated into pCR2.1 in a 10 µL reaction containing 1X ligation buffer (TA 
Cloning Kit, Invitrogen), ~50 ng pCR2.1 vector, ~10 ng fresh PCR product and 4 Weiss 
units of Quickligase (Invitrogen).  The contents were incubated at room temperature for 
10 min and stored at -20ºC. 
 
2.2.3.4 Bacterial Cell Transformation 
For transformations, an aliquot of frozen INVaF’ competent cells was thawed on 
ice.  The ligation reaction (3 μL) was added to the cells and placed on ice for 30 min 
followed by a 30 sec heat shock at 42°C.  The reaction vial was placed on ice for 2 min 
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before 250 μL of pre-warmed SOC (2.0% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 
mM KCl, 10 mM MgCl2-6H2O, 20 mM glucose) medium was added.  The cells were 
shaken at 37°C for 1 hr at 225 rpm in a gyratory shaker. 
To ensure that isolated colonies would be formed, 100 μL and 150 μL of 
transformed competent cells were plated on 100 mm diameter plates of LB agar 
containing 100 μg/mL ampicillin and 40 μL of 20 mg/mL X-gal (5-Bromo-4-chloro-3-
indolyl-β-D-galactopyranoside) from Invitrogen.  The plates were incubated at 37°C 
overnight.  Cells transformed with a successfully ligated pCR2.1 construct formed white 
colonies, while those that retained the uninterrupted lacZα gene fragment formed blue 
colonies.  Several white colonies were streaked on additional LB agar plates containing 
100 μg/mL ampicillin for further analysis. 
 
2.2.3.5 Plasmid DNA Isolation 
A 2-5 mL LB broth (+100 μg/mL amp) culture was inoculated with a wire loop of 
bacterial transformant and incubated overnight in a shaker at 300 rpm and 37°C.  The 
following day, 1.5-3.0 mL of bacterial culture was centrifuged at 9600 x g for 30-60 sec.  
The supernatant was aspirated off and the pellet was resuspended in QIA mini-prep-kit 
buffer P1 (Qiagen).  Plasmid DNA was isolated according to the manufacturer’s 
instructions. 
For storage of bacterial stocks for later use, 0.75 mL of bacterial culture was 
combined with 0.75 mL of glycerol, mixed by inversion and stored at –70°C. 
To determine if the isolated plasmid DNA contained the insert of interest, it was 
digested with the restriction enzyme, EcoRI.  In a 0.5 mL microfuge tube, 4 μL of the 
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mini-prep DNA was mixed with 5-10 U of the appropriate restriction enzyme, and the 
compatible quantity of 10 X One-Phor-All Plus (100 mM Tris-acetate, pH 7.5, 100 mM 
magnesium acetate, 500 mM potassium acetate) (Amersham Pharmacia) buffer in a final 
volume of 10 µL.  The digestion reaction was incubated at 37°C for a minimum of 1 hr, 
after which the entire reaction volume was mixed with DNA running buffer and 
electrophoresed on a 1% TAE agarose gel accompanied by a DNA marker. 
 
2.2.3.6 DNA Sequencing 
All DNA sequencing was performed at the National Research Council (NRC) 
Plant Biotechnology Institute (PBI) DNA Technologies Unit using an automated ABI 
Prism sequencing apparatus. 
 
2.2.3.7 Combined Bisulfite Restriction Analysis (COBRA) 
 Methylation profiles were determined using bisulfite-PCR followed by restriction 
digestion.  Ambiguous primers were used to amplify the CpG island in sodium bisulfite 
modified DNA.  The PCR products were purified using the QIAquick PCR Purification 
Kit (Qiagen).  The amplified fragments were digested with restriction enzymes that digest 
DNA only if the CpG sites in their recognition sequences are methylated: HpyCH4IV or 
BstUI (New England Biolabs).  Digestion with an enzyme that digests DNA only if 
sodium bisulfite modification of the DNA is incomplete was used as a control: CviAII 
(New England Biolabs).  Universally methylated human DNA (Chemicon International) 
or rat DNA, methylated in vitro by CpG methylase (SssI; New England Biolabs) was used 
as a positive control. In a 0.5 mL microfuge tube, 500-700 ng DNA was mixed with 2.5-5 
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U of the appropriate enzyme and 5 μL of the compatible 10X enzyme buffer in a final 
reaction volume of 50 μL.  NEBuffer 1 (10 mM Bis Tris Propane-HCl, 10 mM MgCl2, 1 
mM dithiothreitol, pH 7.0) was used with HpyCH4IV, NEBuffer 2 (50 mM NaCl, 10 mM 
Tris-HCl, 10 mM MgCl2, 1 mM dithiothreitol, pH 7.9) was used with BstUI, and 
NEBuffer 4 (50 mM potassium acetate, 20 mM Tris acetate, 10 mM magnesium acetate, 
1 mM dithiothreitol, pH 7.9) was used with CviAII.  Digestions were carried out for 1 hr 
at 25º, 37º and 60º for CviAII, HpyCH4IV and BstUI, respectively.  The reaction products 
were separated electrophoretically on a 2% TAE agarose gel and stained with ethidium 
bromide.  The proportion of methylated versus unmethylated product (digested versus 
undigested) was quantitated by densitometric analysis, determining the density of 
methylation. Densitometric analysis was performed using a Bio-Rad Geldoc digital 
analyzer equipped with Quantity One version 4.3.1 software. 
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3.0 RESULTS 
 
3.1 MS-1 Comparative Genomics 
The rMS-1 gene is located on chromosome 3q24 of the rat genome, whereas the 
hMS-1 gene is located on chromosome 11p11.2 of the human genome.  The rMS-1 and 
hMS-1 genes both have two CpG islands in the 5’ region, one surrounding the first exon 
and one between the first and second exons.  Due to its location in the promoter region, 
the upstream CpG island was investigated for involvement in epigenetic regulation.  This 
CpG island in rMS-1 is 644 bp in length and contains 58 CpG dinucleotides, whereas the 
hMS-1 CpG island is 671 bp in length and contains 51 CpG dinucleotides.  The rMS-1 
gene generates a 2672 bp mRNA transcript while the hMS-1 gene generates a 2370 bp 
mRNA transcript, both consist of twelve exons. The mRNA sequence of rMS-1 shares 
75% of its sequence with the mRNA of hMS-1 (Figure 3.2). The ORF of rMS-1 encodes 
a 520 amino acid protein, whereas the ORF of hMS-1 encodes a 519 amino acid protein. 
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Figure 3.1 MS-1 gene.   
The promoter region is highlighted in yellow, untranslated regions are purple, exons are 
green, introns are white, CpG islands are highlighted in blue, the putative transcriptional 
start site is indicated by a red arrow and the translational start site by a black arrow. 
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 Figure 3.2 Aligned rMS-1 and hMS-1 mRNA sequences.  Regions of homology are 
highlighted. 
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3.2 Induction of MS-1 Expression 
 
3.2.1 MS-1 Induction following DAC and TSA Treatment 
The mechanism by which MS-1 expression is lost in cells of high metastatic 
potential was unclear.  Southern analyses indicate the presence of the MS-1 gene in all rat 
and human cell lines investigated, suggesting that regulation mechanisms and not LOH 
are responsible for differential expression [34].  The presence of a CpG island 
surrounding the first exon of MS-1 points to epigenetic mechanisms as possible modes of 
regulation.  DNMT and HDAC inhibitors can be used to reverse epigenetic gene 
silencing.  Previously obtained data suggest gene expression may be induced in LN4 or 
MDA-MB-435 cells by treatment with a DNMT inhibitor and a histone deacetylase 
inhibitor [33] [34].   
 5-aza-2’-deoxycytidine (DAC) inhibits DNA methyltransferases (DNMTs), which 
are responsible for transferring the methylation profile of parental strands to daughter 
strands during DNA replication.  Therefore, DAC requires 96 hours to fully deplete the 
DNA of methylation.  Trichostatin A (TSA) is a histone deacetylase inhibitor.  HDACs 
are responsible for removing acetyl groups from histone proteins.  Acetyl groups are 
important for retaining a loose chromatin structure necessary for transcription. 
 To investigate the possible role of epigenetics in the regulation of MS-1, highly 
(LN4, MDA-MB-435) and poorly (CAb, Hs578T) metastatic rat and human cell line pairs 
were treated with 1 µM DAC for 96 hrs followed by 1 µM TSA for 0, 3, 6, 12 or 24 hrs.  
Following drug treatments, total RNA was isolated from the cells and gel electrophoresis 
and Northern blotting was performed to detect the level of MS-1 expression.  Quantitation 
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using a phosphor imager revealed that, although treatment for 96h with DAC or 24h with 
TSA alone caused an average induction of rMS-1 expression in LN4 cells 4-fold and 3-
fold, respectively, the greatest average induction, 12-fold, occurred when both drugs were 
used in conjunction (Figure 3.3).  On average, hMS-1 expression was induced 4-fold in 
MDA.MB.435 cells at 96h DAC plus 24h TSA (Figure 3.4).  These observations suggest 
that both DNA methylation and histone deacetylation may be involved in epigenetically 
silencing the MS-1 gene in highly metastatic LN4 and MDA-MB-435 cells.  In order to 
validate this observation, a more extensive examination of the methylation status of the 
MS-1 CpG islands was carried out.  
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Figure 3.3 DAC and TSA induced rMS-1 expression.   
A. CAb and LN4 cells were treated with 1 μM 5-aza-2’-deoxycytidine (DAC) and/or 1 
μM Trichostatin A (TSA).  A total of 10 μg of total RNA was loaded in each lane, 
transferred and probed with a 565 bp rMS-1 specific cDNA probe or rat GAPDH specific 
cDNA probe.  B. Graphical overview of triplicate Northern analyses.  Each bar represents 
a single experiment (n=3). 
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Figure 3.4 DAC and TSA induced hMS-1 expression.   
A. Hs578T and MDA-MB-435 cells were treated with 1 μM 5-aza-2’-deoxycytidine 
(DAC) and/or 1 μM Trichostatin A (TSA).  A total of 10 μg of total RNA was loaded in 
each lane, transferred and probed with a 558 bp hMS-1 cDNA specific probe or 452 bp 
human GAPDH specific cDNA probe.  B. Graphical overview of triplicate Northern 
analyses.  Each bar represents a single experiment (n=3).   
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3.2.2 MS-1 Induction following SAM Treatment 
 Since the methylation profile of a CpG island is determined by a balance between 
DNMT and demethylase activity, inhibition of demethylase should increase CpG 
methylation and reduce expression of genes with normally unmethylated promoter 
regions.  It has been shown that S-adenosylmethionine (SAM) actively inhibits 
demethylase and can reduce expression of the metastasis-promoting gene urokinase 
plasminogen activator (uPA) [1], and has been proposed as a potential anti-cancer 
treatment [19].  To investigate the specificity of SAM, both rat and human highly (LN4, 
MDA-MB-435) and poorly (CAb, Hs578T) metastatic cell line pairs were treated for 6 
days with 0.1 mM SAM, total RNA extracted and Northern analysis was performed.  
Quantitation using a phosphor imager revealed an induction, not reduction, of MS-1 
expression in already expressing, poorly metastatic cells.  An average 3-fold induction of 
rMS-1 was observed in CAb cells (Figure 3.5) and an average 2-fold induction of hMS-1 
in Hs578T human cells (Figure 3.6).  These results suggest that SAM treatment may alter 
gene expression by mechanisms other than inhibiting demethylase actively.  In order to 
shed light on whether the induction of MS-1 expression is methylation-independent, a 
more extensive investigation of the methylation status of the CpG islands following SAM 
treatment was carried out. 
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Figure 3.5 SAM induced rMS-1 expression.  
A. CAb and LN4 cells were treated with 0.1mM S-adenosylmethionine (SAM) for 6 days.  
A total of 10 μg of total RNA was loaded in each lane, transferred and probed with a 565 
bp rat MS-1 specific cDNA probe or 452 bp rat GAPDH specific cDNA probe.               
B. Graphical overview of triplicate Northern analysis.  Each bar represents a single 
experiment (n=3).   
 
 
 
 
 
 
 
 
Figure 3.6 SAM induced hMS-1 expression.   
A. Hs578T and MDA-MB-435 cells were treated with 0.1mM S-adenosylmethionine 
(SAM) for 6 days.  A total of 10 μg of total RNA was loaded in each lane, transferred and 
probed with a 558 bp human MS-1 cDNA specific probe or 452 bp human GAPDH 
specific cDNA probe.  B. Graphical overview of triplicate Northern analysis.  Each bar 
represents a single experiment (n=3).   
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3.3 Methylation Profiles of MS-1 CpG Islands 
 
3.3.1 Methylation of CpG Islands in Cells that do not express MS-1 
Two methods were utilized to investigate the methylation profiles of the CpG 
islands of MS-1 in various cell lines: combined bisulfite restriction analysis and bisulfite 
sequencing.  The first method used was bisulfite sequencing.  Sodium bisulfite 
deaminates unmethylated cytosines but does not modify methylated cytosine bases, 
discriminating between methylated and unmethylated cytosines of CpG islands.  The 
outside and nested primers designed to amplify modified DNA were ambiguous, 
selecting for neither methylated nor unmethylated DNA.  Primer sets SAC-265/266 and 
SAC-267/257 amplified the CpG island of rMS-1, while SAC-304/305 and SAC-306/307 
amplified the CpG island of hMS-1 (Table 2.1).  The PCR products were purified, cloned 
into the vector pCR2.1, and three clones were sequenced.  The number of deaminated 
nonCpG cytosines divided by the total number of nonCpG cytosines gave a percent of 
modification in each sample.  The number of CpG cytosines protected from deamination 
by a methyl group divided by the total number of CpG dinucleotides gave a percent of 
methylation in each sample.  The percent methylation was then multiplied by the percent 
modification to give a standardized percent methylation. 
All samples, except those from LN4 DNA, showed 97-100% modification, 
indicating that the sodium bisulfite had deaminated nearly all nonCpG cytosines and the 
treatment had gone to near completion.  After several attempts, LN4 DNA was, at most, 
64-71% modified by sodium bisulfite, for unknown reasons.  For MS-1 expressing cell 
lines CAb and Hs578T, the CpG islands revealed an average standardized methylation of 
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2.8% and 0%, respectively.  The CpG islands of the cell lines that did not express MS-1, 
LN4 and MDA-MB-435, showed an average standardized methylation of 38.7% and 
69.2%, respectively.  Following treatment with DAC and TSA, the average standardized 
methylation fell to 19.5% and 33.1% in the CpG islands of LN4 and MDA-MB-435, 
respectively.  These data indicate a correlation between hypermethylation of the CpG 
island and lack of MS-1 expression.  Also, DNMT and HDAC inhibition resulted in a 
significant depletion in the methylation of these CpG islands. 
 
Table 3.1 Triplicate bisulfite sequencing analysis of rMS-1 and hMS-1 CpG islands. 
Sample Percent 
Modification 
Percent 
Methylation 
Standard % 
Methylation 
Average 
CAb 1 99 0 0  
CAb 2  97 8.6 8.4 2.8 
CAb 3 99 0 0  
LN4 1 64 53.5 34.4  
LN4 2 65 53.5 35.0 38.7 
LN4 3 71 65.5 46.6  
LN4 DAC+TSA 1 100 0 0  
LN4 DAC+TSA 2 100 29.3 29.3 19.5 
LN4 DAC+TSA 3 100 29.3 29.3  
Hs578T 1 100 0 0  
Hs578T 2 100 0 0 0 
Hs578T 3 100 0 0  
MDA-MB-435 1 100 62.8 62.8  
MDA-MB-435 2 100 74.5 74.5 69.2 
MDA-MB-435 3 100 70.6 70.6  
435 DAC+TSA 1 98.9 27.5 27.2  
435 DAC+TSA 2 99.5 7.8 7.8 33.1 
435 DAC+TSA 3 99.5 64.7 64.4  
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Figure 3.7 Methylation profiles of rMS-1 CpG Island 58 and hMS-1 CpG Island 51.  
Bars indicate CpG dinucleotides and black triangles indicate methylation, detected 
following triplicate bisulfite sequencing analysis. 
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Figure 3.8 Representative sequences of the MS-1 CpG islands.   
A. rMS-1 sequence analysis.  B. hMS-1 sequence analysis.  C. Graphical overview of the 
average bisulfite sequencing results from three individually cloned PCR products. 
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3.3.2 Screening Various Cancer Cell Lines for Methylation 
 The second method used to investigate the methylation profiles of the MS-1 CpG 
islands was combined bisulfite restriction analysis.  The same primers used to amplify the 
rMS-1 and hMS-1 CpG islands for bisulfite sequencing were also used for restriction 
analysis (Table 2.1).  Restriction digestion was performed using a control enzyme, 
CviAII, which cuts at CATG sites.  Following bisulfite modification these sites should be 
eliminated, and only unmodified DNA will be digested.  Therefore, the proportion of 
DNA undigested versus digested by this enzyme was used to calculate the percent 
modification for each sample.  Enzymes HpyCH4IV and BstUI cut at ACGT and CGCG 
sites, respectively, and thus digest only unmodified DNA and methylated DNA following 
bisulfite modification.  The proportion of DNA digested versus undigested by these 
enzymes was quantitated by densitometric analysis in order to determine the density of 
methylation.  The results from enzymes HpyCH4IV and BstUI were combined to give an 
average percent methylation of the CpG islands from each sample. 
COBRA was performed on both rat and human poorly and highly metastatic 
cancer cell lines in order to determine the CpG island methylation profiles.  Of the rat cell 
lines, CAb and AT1 are both poorly metastatic, MS-1 expressing cell lines, whereas LN4 
and MAT-LyLu are highly metastatic cell lines that do not express MS-1 (Figure 1.3).  
SssI CpG methylase treated CAb DNA was included as a positive control.  Of the human 
cell lines, Hs578Bst, Hs578T, WiDr and MDA-MB-231 expressed MS-1, although 
MDA-MB-231 was a low expresser, whereas MDA-MB-435, MCF-7, T-47D, HEY, 
SW480 and SW620 did not express MS-1 (Figure 1.4).  Universally methylated human 
DNA (Chemicon International) was included as a positive control. 
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The CpG islands from SssI CAb, LN4, LN4 DAC + TSA, LN4 SAM and MAT-
LyLu showed an average methylation of 59.3%, 58.6%, 28.7%, 33.0% and 13.5%, 
respectively.  The CpG islands of CAb, CAb DAC + TSA, CAb SAM and AT1 contained 
an average methylation of 7.6%, 5.1%, 3.4% and 2.0%, respectively (Figure 3.10).  The 
CpG islands from universally methylated human DNA, MDA-MB-435, 435 DAC + 
TSA, 435 SAM, MCF-7, HEY, SW480 and SW620 showed an average methylation of 
92.7%, 75.1%, 16.4%, 65.8%, 41.0%, 45.3%, 15.5% and 28.8%, respectively.  The CpG 
islands of Hs578T, Hs578T DAC + TSA, Hs578T SAM, Hs578Bst, MDA-MB-231, T-
47D and WiDr all contained an average of 0.3-1.7% methylation (Figure 3.11).  In all 
DNA samples, excluding T-47D, methylation within the CpG island corresponds to a 
lack of MS-1 expression. 
Following treatment with DAC and TSA, a decrease in methylation of the CpG 
islands in both LN4 and MDA.MB.435 cell lines was observed.  These results suggest 
that inhibition of DNMTs and HDACs can reduce the amount of methylation within a 
CpG island.  However, treatment with SAM resulted in no change of methylation in the 
CpG island of CAb or Hs578T cells.  It was predicted that SAM inhibition of 
demethylase would increase methylation of CpG islands and reduce expression of MS-1.  
However, from Northern analysis an increase in MS-1 expression was observed in CAb 
and Hs578T cell lines.  Together, these data suggest that the induction of MS-1 
expression by SAM treatment resulted from a methylation-independent mechanism. 
 
 
Figure 3.9 Restriction maps of rMS-1 CpG Island 58 and hMS-1 CpG Island 51. 
856 bp
C HHHBBBB B BB
995bp
C CH HB B B B
rMS-1
hMS-1
HB
Restriction sites for CviAII (C), HpyCH4IV (H) and BstUI (B) are indicated. 
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Figure 3.10 Combined Bisulfite Restriction Analysis of rMS-1 CpG Island 58.   
A. Restriction digests of 500-700 ng DNA with 2.5-5 U of each enzyme for 1 hr at the 
appropriate temperature.  Reaction products were separated electrophoretically on a 2% 
TAE agarose gel and stained with ethidium bromide.  Densitometric analysis was 
performed using a Bio-Rad Geldoc digital analyzer equipped with Quantity One version 
4.3.1 software.  B. Graphical overview of COBRA. 
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Figure 3.11 Combined Bisulfite Restriction Analysis of hMS-1 CpG Island 51.   
A. Restriction digests of 500-700 ng DNA with 2.5-5 U of each enzyme for 1 hr at the 
appropriate temperature.  Reaction products were separated electrophoretically on a 2% 
TAE agarose gel and stained with ethidium bromide.  Densitometric analysis was 
performed using a Bio-Rad Geldoc digital analyzer equipped with Quantity One version 
4.3.1 software.  B. Graphical overview of COBRA. 
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4.0 DISCUSSION 
 
4.1 MS-1 Expression in Cells of Different Metastatic Potential 
Highly metastatic and poorly metastatic subpopulations derived from the same 
tumour allow for the identification of genes that are differentially expressed between the 
subpopulations and thus, may be involved in the metastatic phenotype.  A highly 
metastatic subpopulation, LN4, and poorly metastatic subpopulation, CAb were derived 
from the R3230AC rat mammary adenocarcinoma.  A novel gene, termed MS-1, was 
found to be differentially expressed between these two cell subpopulations.  Although 
high expression was observed in the poorly metastatic CAb subpopulation, LN4 cells 
showed no expression of this gene [33].   
Upon examination of other rat and human, highly and poorly metastatic cell lines, 
a similar pattern of expression was observed.  Highly metastatic rat prostate cells, MAT-
LyLu, did not express MS-1 but the poorly metastatic counterpart, AT1, showed high 
expression [33].  MS-1 expression was undetectable in human mammary adenocarcinoma 
cell lines T-47D, MCF-7 and MDA-MB-435, and was observed at low levels in the 
MDA-MB-231, which were all developed from metastatic pleural effusions.  MS-1 
expression was also not observed in the human ovarian cancer cell line, HEY, highly 
metastatic human colon cancer cell line, SW620, or its poorly metastatic counterpart, 
SW480.  MS-1 expression was detected in a human normal mammary cell line, 
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Hs578Bst, the corresponding primary ductal carcinoma cell line, Hs578T and a poorly 
metastatic human colon cancer cell line, WiDr [34].   
In most cell lines examined, MS-1 expression appears to correlate with a poorly 
metastatic phenotype, implicating a possible role for MS-1 in suppressing metastasis.  
Metastasis suppressor gene BRMS1 is located on chromosome 11q13.1-13.2, a region 
commonly altered in late-stage breast carcinomas [4].  Metastasis suppressor gene Kai1 is 
located on chromosome 11p11.2, a region commonly associated with breast cancer 
progression [4].  Introduction of human chromosome 11 into rat prostate cancer cells of 
high metastatic potential resulted in metastasis suppression without affecting growth rate 
or tumourigenicity [50].  The region between 11p11.2-13 was determined to be the 
minimal portion of human chromosome 11 capable of suppressing metastasis [51].  The 
location of the hMS-1 gene on chromosome 11p11.2 of the human genome is consistent 
with the possibility that it may play a role in metastasis suppression.  However, any 
evidence supporting the involvement of MS-1 in metastasis, if any, remains to be 
determined. 
The mechanism by which MS-1 expression is lost or down-regulated in cells of 
high metastatic potential is unknown.  Although its expression was not observed in 
MDA-MB-435, MCF-7 and T-47D cells following Northern analysis, Southern analysis 
revealed that these cell lines all retained both copies of the hMS-1 gene [34].  Therefore, 
LOH does not appear to be the mechanism by which MS-1 expression was lost.   
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4.2 Epigenetic Regulation  
A common mechanism for gene silencing is DNA methylation and chromatin 
remodelling.  Methylated DNA, deacetylated histones, some methylated histone forms 
and condensed chromatin are associated with inaccessible DNA and repressed or silenced 
gene expression.  However, unmethylated DNA, acetylated histone forms and open 
chromatin are associated with active or potential gene expression [6].  DNA methylation 
occurs at cytosine residues of CpG dinucleotides.  The CpG dinucleotide has been 
progressively depleted from the eukaryotic genome and is found at 1/5 of the expected 
frequency.  Remaining CpG dinucleotides outside of CpG islands have a high incidence, 
~70%, of methylation [8] [13].  Small stretches in the genome (0.5 to 2kb) contain the 
expected frequency of CpGs (G/C content of 50% or higher and an observed 
CpG/expected CpG of 0.60 or higher), and are referred to as CpG islands [8] [15].  The 
presence of a CpG island in the 5’ region of the MS-1 gene suggests that epigenetic 
mechanisms may be involved in MS-1 gene silencing. 
 An investigation of the methylation status of the 5’ MS-1 CpG islands was carried 
out to determine a role of methylation in epigenetic regulation of this gene.  Bisulfite 
sequencing revealed that the CpG islands of MS-1 expressing cell lines, CAb and 
Hs578T, contained no significant methylation.  Only the CpG islands of MS-1 in the cell 
lines that show no expression, LN4 and MDA-MB-435, were significantly methylated 
(Table 3.1 and Figure 3.8).  Combined bisulfite restriction analysis was performed to 
screen CpG islands from several rat and human cancer cell lines.  Again, the CpG islands 
of MS-1 in expressing cell lines, CAb, AT1, Hs578T, Hs578Bst, MDA-MB-231 and 
WiDr, were not significantly methylated.  However, the CpG islands of MS-1 in cell lines 
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that show no expression, LN4, MAT-LyLu, MDA-MB-435, MCF-7, HEY, SW480 and 
SW620, contained significant methylation (Figures 3.10 and 3.11).  With the exception of 
T-47D, which does not express MS-1 but whose CpG island was unmethylated, these data 
indicate a correlation between hypermethylation of the CpG island and lack of MS-1 
expression in various cancer cell lines.  
 It has been hypothesized that methylation is a third pathway, in addition to 
intragenic mutations and loss of chromosomal material, for complete inactivation of a 
gene [52].  Although Southern analysis ruled out LOH as reason for MS-1 gene 
inactivation, it is possible that mutations may contribute to loss of MS-1 gene expression.  
Perhaps in the T-47D cell line intragenic mutations, without promoter methylation, are 
responsible for MS-1 gene inactivation.  
 
4.3 Inhibition of DNA Methyltransferase and Histone Deacetylase Activity 
Demethylation and histone deacetylase inhibition can be induced by the addition 
of epigenetic regulators to cells in vitro.  The DNA methyltransferase inhibitor, DAC, 
and histone deacetylase inhibitor, TSA, can be used to reverse epigenetic silencing.  
Although treatment with DAC or TSA alone can induce expression of rMS-1 in LN4 cells 
4-fold and 3-fold, respectively, the greatest average induction occurs when both drugs are 
used in conjunction, 12-fold (Figure 3.3).  hMS-1 expression is induced 4-fold in MDA-
MB-435 cells following treatment with DAC plus TSA (Figure 3.4).  These results 
indicate that DNA methylation and histone deacetylation may play individual roles in the 
process of epigenetic silencing but that there exists a link between the two mechanisms, 
allowing them to work in concert.  Methyl-CpG-binding proteins can recruit histone-
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modifying complexes to methylated cytosines, inducing the formation of compact 
chromatin and rendering the locus less accessible to necessary transcription factors [6].  
Therefore, it has been proposed that methyl-CpG-binding proteins serve as a bridge 
between the two major epigenetic mechanisms, DNA methylation and histone 
modification [17]. 
The induction of MS-1 expression by DAC and TSA as shown in Figures 3.4 and 
3.5 supports the hypothesis that both DNA methylation and histone deacetylation may be 
involved in epigenetically regulating the MS-1 gene in highly metastatic LN4 and MDA-
MB-435 cells.  Examination of the methylation status of the MS-1 CpG islands following 
inhibition of DNA methyltransferase and histone deacetylase activities was used to verify 
whether changes in methylation are responsible for the changes in expression. 
Bisulfite sequencing revealed that, following treatment with DAC and TSA, the 
average methylation of the MS-1 CpG islands was reduced by 50% in the highly 
metastatic cells, LN4 and MDA-MB-435 (Figure 3.8).  These observations validate that 
the induction of MS-1 expression by DNA methyltransferase and histone deacetylase 
inhibition occurred alongside a significant depletion in the methylation of the MS-1 CpG 
islands.  The results obtained from the combined bisulfite restriction analysis confirmed 
the observations made from bisulfite sequencing and Northern analysis.  Following 
treatment with DAC and TSA, a 50% or greater decrease in methylation of the CpG 
islands in both LN4 and MDA-MB-435 cell lines was seen (Figures 3.10 and 3.11).  
Together, these results support the hypothesis that inhibition of DNA methyltransferase 
and histone deacetylase activity reduces the amount of methylation within the MS-1 CpG 
islands, resulting in MS-1 expression. 
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4.4 Inhibition of Demethylase Activity 
Since the methylation profile of a CpG island may result from a balance between 
DNMT and demethylase activity, inhibition of demethylase may increase CpG 
methylation and reduce expression of genes with normally unmethylated promoter 
regions.  This was demonstrated with the pro-metastatic gene, urokinase Plasminogen 
activator (uPA) [1].  It was predicted that SAM inhibition of demethylase would increase 
methylation of CpG islands and reduce expression of MS-1 in expressing cell lines, CAb 
and Hs578T.  However, it was demonstrated through combined bisulfite restriction 
analysis that treatment with SAM resulted in no significant change of methylation in the 
CpG island of CAb or Hs578T cells (Figures 3.10 and 3.11).    Also, Northern analysis 
indicated an average 3-fold and 2-fold induction of MS-1 in CAb and Hs578T cell lines, 
respectively (Figures 3.5 and 3.6).  Together, these data suggest that the induction of MS-
1 expression by SAM treatment was caused by a methylation-independent mechanism. 
The methylation-independent induction of MS-1 by SAM, observed in CAb and 
Hs578T cells, contradicts the role of SAM as a demethylase inhibitor.  However, other 
examples exist where drugs used for epigenetic therapy contradict the traditional model 
for epigenetic silencing.  The mechanism by which HDAC inhibitors bring about changes 
in gene expression is poorly understood but is generally assumed to result from local 
changes in histone acetylation status. The observation that many common co-activators 
such as p300 have intrinsic HAT activity, while repressor complexes such as Sin3 are 
associated with HDAC activity, has strengthened this model [53].  Following this model, 
TSA, a known histone deacetylase inhibitor, contributes to alleviating the compact 
chromatin structure of transcriptionally silent genes.  However, this does not fully explain 
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its role in regulating gene expression.  It has been well characterized that treatment with 
TSA leads to the induction of p21WAF1, which mediates cell cycle arrest, and to the 
inhibition of c-myc, which mediates proliferation and differentiation.  Treatment with 
TSA also represses expression of c-Src, a known oncogene, in various cell lines including 
T-47D, a human breast cancer cell line [53].   
Histone deacetylase inhibitors are described as having anti-cancer activity, 
inducing cell cycle arrest, differentiation and apoptosis.  These properties are presumed to 
result from highly selective gene expression changes.  It has been shown through 
microarray and differential display analysis that TSA acts on only a small subset (~2%) 
of genes [54].  Therefore, in contrast to the idea of HDACs as master and global 
regulators of transcription, it appears that inhibition of HDAC leads to a fairly restricted 
alteration of gene expression profile which, in turn, may explain the apparent low toxicity 
seen in clinical trials.  To date, genes which are modulated by HDAC inhibitors suggest a 
pleiotropic effect on key pathways involved with proliferation, apoptosis, tumour 
suppressors, DNA synthesis and repair, and protein turnover [10].   
Although local acetylation changes can explain the induction of genes via histone 
deacetylase inhibitors, it is more difficult to explain the mechanism of gene repression by 
this treatment.  Since histone acetyltransferases (HATs) are capable of acetylating non-
histone proteins, it has been presumed that HDAC inhibitors can mediate the down-
regulation of genes in a histone acetylation/deacetylation-independent manner [53].  To 
support this, studies have shown that the induction of specific serine/threonine 
phosphatases were required for the repression of c-myc by an HDAC inhibitor.  
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Therefore, a revised model of how HDAC inhibitors alter gene expression may include 
phosphorylation events as well as histone modifications [53]. 
Likewise, the traditional model of epigenetic silencing defines SAM as a methyl 
donor and inhibitor of active demethylation [1].  Studies on the pro-metastatic gene, uPA, 
shows that SAM treatment causes hypermethylation of the gene’s promoter region, 
inhibition of the gene’s expression and decreased invasiveness of normally metastatic 
breast cancer cells, MDA-MB-231 [1].  However, microarray analysis has shown that 
SAM treatment induced Bcl-xS expression, a pro-apoptotic factor.  Just as HDAC 
inhibitor TSA is defined both by its role in epigenetics and by its anti-cancer properties, 
demethylase inhibitor SAM is defined by its role in epigenetics and by anti-cancer 
characteristics.  There are extensive data from animal as well as some human data that 
suggests dietary intake of folates, which are required for the synthesis of SAM, can 
influence cancer progression.  It was shown in animal studies that low methyl diets could 
induce liver cancer. Human studies suggest that low folate intake combined with high 
alcohol intake could result in an increased risk of colorectal cancer. There is also some 
evidence that folate metabolism and the resultant supply of methyl moieties might play a 
role in breast cancer since pre-menopausal women with the polymorphism in methylene-
tetrahydrofolate reductase (MTHFR), an enzyme required for the synthesis of 
methionine, a precursor of SAM, had a three-fold increased breast cancer risk. SAM was 
shown to be chemoprotective for liver cancer in chemically induced rat liver cancer [1]. 
Also, just as TSA utilizes both acetylation/deacetylation-dependent and 
acetylation/deacetylation-independent mechanisms to regulate gene expression, SAM can 
alter gene expression via methylation-dependent and methylation-independent 
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mechanisms.  Recent evidence suggests that in the liver, SAM has critical functions in 
modulating growth and apoptotic responses, some of which are independent of 
methylation because they can be mimicked by 5’-methylthioadenosine (MTA), which is 
not a methyl donor.  Both SAM and MTA selectively up-regulated Bcl-xS expression in a 
time- and dose-dependent fashion, with the effective dose for MTA lower than that for 
SAM, suggesting that the effect of SAM may be mediated in part by MTA [55].  
Although MTA is a metabolite of SAM, it can also be converted back to SAM via 
methionine.  However, blocking this conversion did not prevent the induction of Bcl-xS 
expression by MTA, supporting the notion that MTA exerts its action directly.  Inhibitors 
of histone deacetylase and DNA methylation also had no effect on the induction of Bcl-xS 
expression by SAM and MTA, thereby excluding their involvement [55]. 
Finally, just as the induction of specific serine/threonine phosphatases is required 
for the repression of c-myc by an HDAC inhibitor, inhibition of specific serine/threonine 
phosphatases nullifies SAM and MTA induction of Bcl-xS [55].  Therefore, a revised 
model of how demethylase inhibitors specifically alter gene expression may include 
phosphorylation events to induce anti-cancer factors as well as DNA modifications to 
repress genes involved in cancer and metastasis progression. 
 
4.5 Conclusions 
 An inverse relationship exists between the expression of MS-1 and metastatic 
phenotype in most cell lines studied.  Data from bisulfite sequencing and combined 
bisulfite restriction analysis confirmed that hypermethylation of the rMS-1 and hMS-1 
CpG islands correlates with the lack of MS-1 expression.  MS-1 expression can be 
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induced in non-expressing cells of high metastatic potential following DNA 
methyltransferase and histone deacetylase inhibition.  This induction occurred following 
hypomethylation of the CpG islands, confirmed by bisulfite sequencing and combined 
bisulfite restriction analysis.  Therefore, epigenetic silencing via DNA methylation and 
histone deacetylation is one of the mechanisms involved in down-regulating MS-1 
expression in cells of high metastatic potential. 
 MS-1 expression can also be induced in expressing cell lines of low metastatic 
potential following treatment with a demethylase inhibitor.  Data from combined bisulfite 
restriction analysis determined that this induction resulted from no change in the 
methylation status of the CpG island.  Therefore, although inhibiting demethylase with S-
adenosylmethionine can reduce expression of a metastasis-promoting gene in a 
methylation-dependent manner [1], treatment with this drug can also induce gene 
expression of a putative metastasis suppressor through methylation-independent 
mechanism. 
 
4.6 Future Directions 
 The ability to induce MS-1 expression through inhibition of DNMTs presents a 
possible role in breast cancer treatment.  Decitabine, the commercial name for the DNA 
methylation inhibitor DAC, is currently in phase II clinical trials for the treatment of 
patients with chronic myelogenous leukemia [56].  However, the mere observation of an 
inverse relationship between MS-1 expression and metastatic potential does not warrant 
the use of this drug to treat metastatic cancer.  It is extremely important that the role of 
MS-1, if any, in metastasis suppression be identified.  Animal studies are required to 
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determine if the expression of MS-1 can prevent metastasis.  It then needs to be 
determined if the inhibition of DNMTs and HDACs via drug treatments are able to 
induce MS-1 expression in an animal model to the level required to carry out a 
suppressive role.  The expression of MS-1 and/or pro-angiogenic factors needs to be 
investigated in breast cancer cell lines of high and low metastatic potential following ER 
stress to evaluate if the role of MS-1 in the UPR relates to metastasis.  The possible role 
of MS-1 as a transcription factor leads to the hypothesis that the induction of its 
expression may have a complex impact on many cellular functions, which need to be 
examined. 
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